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Abbreviations 
bid twice daily 
CI confidence interval 
EGPS European Glaucoma Prevention Study 
EMGT Early Manifest Glaucoma Trial 
IOP intraocular pressure 
mm Hg millimeters of mercury 
OH ocular hypertension 
OHTS Ocular Hypertension Treatment Study 
POAG primary open-angle glaucoma 
qd once daily 
RCT randomized controlled trial 
RR relative risk 
SD standard deviation 
tid three times daily 
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In this thesis ocular hypertension (OH) and primary open-angle glaucoma (POAG) 
are the main subjects of study. This introduction gives a brief description of OH and 
POAG, an explanation of the study methods and a detailed outline of the thesis. 
Ocular hypertension 
Data from large epidemiologic studies indicate that the mean intraocular pressure 
(IOP) is approximately 16 mm Hg, with a standard deviation of 3 mm Hg.1 The IOP 
distribution is skewed towards higher pressures, especially in individuals over the 
age of 40. The probability of glaucoma development increases with higher IOP 
levels.2-6 A value for the IOP of more than 21 mm Hg is used by clinicians to define 
patients with ocular hypertension (OH), even though below this level individuals 
still can develop glaucoma. Individuals with OH, by definition, have an elevated 
IOP and no detectable glaucomatous damage as assessed by standard clinical eye 
examination and additional visual field examination. They have no symptoms due 
to OH and they have an increased risk of developing POAG.7 The prevalence of 
ocular hypertension found in population studies in several European countries is 
2.2%.8-10 Presently, the intraocular pressure is the only risk factor for POAG that is 
amenable to medical intervention. 
Primary open-angle glaucoma 
Primary open-angle glaucoma (POAG) is a progressive, chronic optic neuropathy in 
adults where intraocular pressure (IOP) and other currently unknown factors con-
tribute to damage and in which, in the absence of other identifiable causes, there is a 
characteristic acquired atrophy of the optic nerve and a loss of retinal ganglion cells 
and their axons.11 In open-angle glaucoma, by definition, the anterior chamber 
angle is open by gonioscopic appearance. When no underlying cause of an elevated 
IOP and a consequent glaucomatous damage can be found, glaucoma is classified as 
primary. In this thesis, primary open-angle glaucoma is referred to as glaucoma. 
Diagnosis 
An initial glaucoma evaluation includes a comprehensive eye evaluation, including 
history to establish risk factors, and physical examination. The IOP, the appearance 
of the optic nerve, and the status of visual field can be evaluated by tonometry, 
ophthalmoscopy and perimetry, retrospectively. In addition, there are several in-
struments available for optic nerve imaging which use computer algorithms, such as 
the scanning laser ophthalmoscope, the retinal nerve fiber analyser, and the optical 
coherence tomograph. 
Prevalence and incidence 
Primary open-angle glaucoma affects about 1-2% of the population, ranging from 
0.2% in 40-50 years old to 4.7% in individuals aged above 80 years.8,10,12 The 
incidence rate is estimated to be 0.1% per year.13 
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Risk factors 
Four important risk factors associated with glaucomatous optic neuropathy are the 
IOP, race (African or Hispanic/Latino descent), age, and family history of glau-
coma.11 The association between POAG and other potential risk factors like low 
diastolic perfusion pressures, diabetes, myopia, and systemic hypertension has not 
been demonstrated consistently. 
Natural history 
Glaucoma is a chronic, slowly progressive, generally bilateral but often asymmetri-
cal disease.14 In the end stages glaucoma produces tunnel vision and finally blind-
ness. In many patients there are no noticeable symptoms until the later stages of the 
disease. Glaucoma is therefore sometimes called the “silent blinder”.15 In the Balti-
more Eye Survey about 50% of people with glaucoma were unaware they had the 
disease.16 Blindness caused by glaucoma is irreversible. The incidence of blindness 
is estimated to be about 1% per year in treated glaucoma patients and about 10% in 
untreated.17-20 
Treatment 
Glaucoma can not be cured. Treatment can stop or delay its progression to blind-
ness.11 Therapy is directed towards lowering the intraocular pressure, which can be 
achieved by means of medication, laser or surgery. Patients are committed to regu-
lar medical check-ups. Glaucoma medication is applied topically and is required 
lifelong. It can cause ocular and systemic side-effects. The purpose of treatment is 
to preserve visual function while minimizing adverse effects of therapy, thereby 
enhancing the patient’s health and quality of life, especially with regard to such 
issues as self-care, driving and working.11 
 
Several types of IOP lowering drugs are now available. The most often used drugs 
are beta-adrenergic antagonists (timolol, betaxolol), carbonic anhydrase inhibitors 
(dorzolamide, brinzolamide and acetazolamide), alpha2-adrenergic agonists (bri-
monidine, apraclonidine) and hypotensive lipids (bimatoprost, latanoprost, travo-
prost). They have a different pharmacokinetic and pharmacodynamic profile. 
Moreover, they differ in IOP lowering effects and adverse events. 
Public health impact 
Glaucoma is the second leading cause of world-wide blindness.21 It has been esti-
mated that there will be 60.5 million people with glaucoma in 2010, increasing to 
79.6 million by 2020, 74% of whom will have POAG. Bilateral blindness will be 
present in 4.5 million people with POAG in 2010, rising to 5.9 million people in 
2020.21 Because of the health, social, and economic consequences of blindness, 
adequate glaucoma management is not only a concern of patients and their physi-
cians, but of the entire society.15 
Early detection and treatment 
As stated above, glaucoma is a slowly progressive disease without symptoms 
during a long time period. Glaucoma is a good candidate for early detection and 
Introduction 
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treatment. The disease can be diagnosed without much burden for the patient and 
effective treatment exists. Moreover, preventive treatment of ocular hypertension is 
an option to reduce glaucoma blindness. 
Methodology 
The goal of the study presented in this thesis is to explore the clinical effects and 
cost-effectiveness of current OH and POAG management and to provide relevant 
information for clinically and socially important decisions regarding early detection 
and treatment of OH and POAG. In the studies different methodology tools are 
used. A systematic review of literature of clinical trials with a meta-analysis is used 
to evaluate the effect on the risk of conversion to glaucoma of medical IOP lower-
ing in OH patients. A case-referent study was designed to study the impact of early 
detection on the prevention of glaucoma blindness. Simulation models, in which the 
clinical experience of glaucoma specialists and the currently available scientific 
evidence are combined, estimate the long-term health-effectiveness. Finally, the 
principles of cost-effectiveness analysis are applied for an evaluation of different 
strategies for OH and POAG management.22 For this purpose the corresponding 
costs have been identified and assigned in the decision models. 
 
In the field of ophthalmology the use of modeling techniques and the methods of 
cost-effectiveness evaluation are increasingly applied. It is common that an eco-
nomic evaluation is formulated in terms of a choice between competing alterna-
tives. The basic tasks of any economic evaluation are to identify, measure, value, 
and compare the costs and consequences of the alternatives being considered.22 In a 
health economic assessment it is of importance that all costs related to detection, 
treatment, and management of the disease, as well as the outcomes of treatment, are 
taken into account.23 When all relevant costs and all outcomes, including adverse 
events and treatment failures, are properly included in the evaluation, a seemingly 
expensive treatment strategy might ultimately turn out to be less costly than a 
seemingly less expensive alternative. Specific for the cost expenditure in glaucoma 
is that costs are being spent in advance, while health benefits predominantly occur 
in the long term. Long-term data are required to estimate therapy effects. Such data 
are, however, difficult to obtain. Clinical trials mostly have a limited follow-up and 
are guided by a strict protocol, so they do not give a true reflection of patient man-
agement in clinical practice. A combination of these data with observational clinical 
data might be a better approach to this problem. Modeling allows to combine data 
from different sources, such as data sets, the literature, systematic reviews or even 
expert opinion in a meaningful way. Models allow real life situations to be repre-
sented in a mathematical or statistical way. A wide range of diagnostic and treat-
ment scenarios can be investigated by varying the influential factors. Moreover, real 
life situations can be simulated to avoid placing individuals at risk and long-term 
progression can be studied in limited time. Mathematical modeling is used widely 
in economic evaluation of pharmaceutical and health care technologies.24 Such 
models, often complex, deal with structural assumptions and parameter estimates. 
Chapter 1 
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To provide modellers with scientific guidelines, the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) has recommended criteria for 
assessing the quality of models, addressing model structure, the data used as input, 
and model validation.24 The models presented in this thesis comply with these 
criteria. 
 
The decision analyses in this thesis are based on state-transition Markov models. A 
Markov model is a useful tool when a decision problem involves recurrent events 
and risk that is continuous over time. A Markov model is comprised of a set of 
mutually exclusive and collectively exhaustive health states.25 Health states may be 
defined according to disease stages, treatment status, or a combination of the two. 
The events are represented in the model as transitions from one state to another. The 
members of a hypothetical population are allocated and subsequently repeatedly 
reallocated into these health states. The reallocation happens at fixed time intervals, 
known as the Markov cycle length according to the defined transition probabilities. 
For instance, with a known yearly probability for patients to develop a disease, 
yearly transitions of patients from a health state ‘well’ to a health state ‘ill’ can be 
simulated. Likewise, progression from an early stage to an advanced stage of a 
disease can be modelled. These transitions may differ per strategy. Transition 
probabilities will often be different for untreated patients compared to patients 
under treatment. To each health state specific values can be assigned, such as costs, 
associated with the required health care related to the particular state. The transi-
tions are repeatedly simulated over a chosen time period. The distribution of the 
population over the health states per cycle determines the quantity of the accumu-
lated costs. The defined health outcomes and the total cost expenditure over the 
modelled time period can be identified per modelled strategy and compared. 
 
In Figure 1 a hypothetical example of a Markov model is given. In this example a 
conversion to a disease and the disease progression over time are modelled. Transi-
tions to a health state ‘dead’ are incorporated as well. The health state ‘dead’ is an 
absorbing state, from where no more transitions are possible, in contradiction to the 
other health states. From the state ‘well’ transitions to the states ‘early stage of 
illness’ and ‘dead’ are possible, which models healthy individuals becoming ill or 
dying. In the given example the mortality rate is illness dependent, but it is inde-
pendent of age and gender. In contrast, in two models in this thesis the mortality 
rate does depend on age and gender, but it is not connected to glaucoma. In those 
models the mortality rate is increasing with each cycle as the simulated population 
is becoming older. 
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Figure 1: On the left: Representation of a Markov model, as a flowchart, with four health-states: ‘well’, ‘early 
stage of illness’, ‘advanced stage of illness’, and ‘dead’, shown as circles. Possible state transitions are 
indicated by arrows, labelled with yearly transition probabilities. On the right: The proportion of the popula-
tion in each state at the beginning of a cycle and the change of this proportion over time is shown. Initially, the 
entire population is situated in the state ‘well’. The distribution of patients among the health states in the 
subsequent cycles is determined by their distribution in the previous cycles and the transition probabilities 
between the states. 
In the models presented in this thesis a decision tree structure is incorporated as 
well. This is used to model events which occur once only, like diagnosing of pa-
tients, or adjustments of medication after the initiation of therapy. In a decision tree 
the sequence of chance events and decisions over time is represented.26 Each chance 
event is assigned a probability. Each path in the decision tree represents one possi-
ble sequence of chance and decision events. 
Outline of the thesis 
The feasibility of screening for glaucoma is a subject of a currently ongoing debate 
among ophthalmologists and health decision makers.27 This is a complex problem 
and despite the recent advances in the diagnosis and treatment of glaucoma it is 
uncertain if glaucoma screening can be effectively and reliably achieved.28 This 
thesis is directed to investigate issues connected to the early detection and treatment 
of ocular hypertension and glaucoma. 
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One of the puzzling controversies in glaucoma management is whether ocular 
hypertension should be treated or not, considering a different susceptibility of 
patients to tolerate high intraocular pressures and the uncertain rate of conversion to 
glaucoma and progression to blindness in treated and untreated patients.11 We have 
estimated the effect of treatment on the conversion to glaucoma in patients with 
ocular hypertension and its progression in patients with early glaucoma through a 
systematic review of randomized clinical trials. This is described in Chapter 2. The 
results of this study help to decide whether patients with OH or early POAG should 
be treated. 
 
The impact of early detection and subsequent treatment of OH or POAG on the 
occurrence of blindness has not been explicitly assessed in the literature. If treat-
ment initiated at an early stage of the disease can prevent the progression to blind-
ness one would expect that patients who did become blind due to glaucoma have 
not been diagnosed in time. These issues are investigated in a case-referent study, 
described in Chapter 3. The results of this study help to decide whether tests to 
detect OH and POAG at an early stage should be applied by ophthalmologists. 
 
A realistic alternative for screening to discover and treat OH and POAG at an early 
stage is case-finding among patients visiting an ophthalmologist. Even though case-
finding strategies are currently being applied by most ophthalmologists, the effects 
of such strategies to prevent glaucoma blindness are unknown. In Chapter 4 a cost-
effectiveness evaluation of different case-finding strategies is given. A simulation 
model is used to compare the lifetime costs and effects of three different strategies. 
The results of this study help to decide which case-finding strategy should be 
applied by an ophthalmologist. 
 
The emergence of new types of glaucoma drugs in the past years has offered better 
opportunities to medically treat patients but also caused a substantial rise of the 
therapy costs.29-31 A broad spectrum of available drugs, which differ in costs and 
effects, which may or may not cause side-effects, which may also be combined, 
allows for a large variety of possible treatment strategies. In practice such strategies 
involve the use of target pressures, which are different for POAG and OH. In order 
to make progress in investigating optimal treatment strategies for OH, we here 
study the question of which drug should be used as a first treatment choice. In 
Chapters 5 and 6 an evaluation of two different strategies for the initiation of OH 
therapy by means of a simulation model is given. Initiation of OH therapy with a 
new topical agent (latanoprost) is compared to initiation by a beta-blocker (timolol). 
The short and long-term clinical consequences of these two strategies are described 
in detail in Chapter 5. In Chapter 6 a cost-effectiveness analysis of these two strate-
gies is presented. The results of these studies help ophthalmologists to decide which 
initial OH medication therapy to apply. 
 
Finally, in Chapter 7 the findings of this thesis are discussed and recommendations 
for further research are given. 
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Abstract 
Objective: To estimate the effect of IOP lowering therapy on the incidence of 
primary open-angle glaucoma (POAG) in patients with ocular hypertension (OH) 
and on the progression in patients with glaucoma. 
Design: Meta-analysis of randomized controlled trials. 
Participants: Nine articles which included OH patients and one article which 
included early glaucoma patients. 
Methods: An electronic search of the databases Medline, Embase and the Cochrane 
Register of Controlled Trials was conducted to identify articles for inclusion. The 
inclusion criteria were: articles written in English, French, German or Dutch; trials 
in OH or POAG; a randomized comparison of intraocular pressure (IOP) lowering 
intervention versus placebo or no treatment; visual field loss or optic disc changes 
as outcome; follow-up longer than 6 months. The methodological quality of the 
selected studies was evaluated by criteria of the Delphi list and the Cochrane Col-
laboration. In a meta-analysis performed for OH trials a pooled relative risk was 
calculated using a ‘random effects model’. A meta-regression analysis was per-
formed to assess the magnitude of the glaucoma risk reduction in OH patients per 
mm Hg of IOP reduction achieved through therapy. 
Outcome measures: Conversion to glaucoma or its progression. 
Results: The search resulted in nine OH trials and one POAG trial, which met the 
inclusion criteria. All individual OH studies show a positive effect of IOP lowering 
on a reduction of the incidence rate of glaucoma. The calculated pooled relative risk 
is 0.61 (95% confidence interval 0.45-0.83). A meta-regression model shows a 
decrease of the relative risk of conversion to glaucoma by 14% with each mm Hg of 
extra IOP reduction (p = 0.045). The only trial, which included glaucoma patients, 
shows a protective effect of hypotensive therapy in early glaucoma. 
Conclusions: There is sufficient evidence that IOP lowering therapy in patients 
with ocular hypertension reduces the risk of conversion to glaucoma. The relative 
risk decreases more with larger IOP reduction. The protective effect of IOP lower-
ing on glaucoma progression is shown by one trial which included patients with 
early visual field loss. 
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Introduction 
An elevated intraocular pressure (IOP) is an important risk factor for a conversion 
to glaucoma in patients with ocular hypertension (OH) and a prognostic factor in 
patients with primary open-angle glaucoma (POAG).1 Medication, laser and surgery 
are used to lower the IOP. The final goal of therapy is to prevent or delay damage to 
the optic nerve and thereby to prevent functional limitations and blindness. 
 
In the past, trials have been carried out which show that lowering the IOP in pa-
tients with glaucoma is beneficial for the prevention of severe visual field loss and 
the usefulness of glaucoma treatment is not questioned.2-6 In these trials a compari-
son is made between different types of hypotensive treatment. The effect of treat-
ment versus no treatment is particularly of interest for OH patients and patients with 
early glaucoma. The susceptibility of the optic nerve to IOP-related damage varies 
among individuals and for many patients treatment may not be considered neces-
sary.1 
 
The efficacy of early detection and treatment in connection with prevention of 
advanced stages of glaucoma with severe visual loss or blindness is closely associ-
ated with the effectiveness of treatment of OH and early POAG. A level of IOP 
achieved by treatment plays a role in this as well. In the current glaucoma manage-
ment an ophthalmologist strives to achieve for each patient an IOP level by which 
protection against optic nerve damage is achieved. The estimated upper limit of 
such IOP level is considered ‘target pressure’. For OH patients a target pressure 
may be viewed as a threshold recommended for initiation of treatment.7 Therefore, 
it is of interest to investigate to what extent a larger IOP reduction in OH patients 
influences the risk of conversion to glaucoma. 
 
In the present study the currently available scientific evidence concerning the 
benefit of treatment in OH and early glaucoma is systematically analysed. A quanti-
fication of the effect of IOP lowering in OH patients on the occurrence of glaucoma 
is performed by combining data of several comparable randomized controlled trials 
in a meta-analysis. Nine OH studies, including two so far largest trials, the Ocular 
Hypertension Treatment Study (OHTS)8 and the European Glaucoma Prevention 
Study (EGPS)9 are included in this meta-analysis. Meta-regression analysis based 
on the outcomes of these nine OH trials determines the magnitude of risk reduction 
of conversion of OH to glaucoma per each extra mm Hg of IOP reduction achieved 
through therapy. 
Methods 
Search strategy 
Articles describing randomized controlled trials (RCT’s) on treatment of patients 
with ocular hypertension or primary open-angle glaucoma were identified through a 
systematic search in the databases Medline, Embase, and the Cochrane Register of 
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Controlled Trials. For search in Medline the modified version, advised by the 
Cochrane Handbook, of the published search strategy of Dickersin was used.10 For 
search in Embase a strategy of Tulder et al was applied.11 
 
Keywords in connection with the disease were: “glaucoma” and “ocular hyperten-
sion”. Keywords in connection with the study outcome were: “visual field”, “dB”, 
“Humphreys”, “Friedman” and “perimetr*”. The ‘thesaurus’ of the databases and 
the ‘explode’ option were utilized. The original search of the databases was done 
until February 2004, but recently the search was updated. Subsequently the refer-
ence lists of the selected articles and of two meta-analysis articles12,13 were con-
sulted until no further studies could be found. Also the result of a search conducted 
in connection with a meta-analysis performed earlier by the authors was checked.14 
Selection of the studies; inclusion criteria 
Two researches (JS and AP) selected independently potential articles to be included 
in the meta-analysis. By viewing the title, abstract and the medical subject heading 
(MeSH) of the articles, a first judgement of the eligibility was done. The potentially 
eligible publications were printed or photocopied for further evaluation. All selected 
articles had to fulfil the following inclusion criteria: 1) language: English, French, 
German or Dutch; 2) disease in question: OH or POAG; 3) randomized comparison: 
IOP lowering intervention versus placebo or no treatment; 4) study outcomes: 
visual field loss or optic disc changes; 5) follow-up longer than 6 months. 
Quality Assessment and Data Abstraction 
Methodological quality of the selected studies was evaluated by the criteria for 
evaluation of RCT’s recommended by the Delphi list,15 the Cochrane Collaboration 
and criteria added by the authors (see Table 1). The quality items used for the 
quality assessment are given in Table 1. Two researchers (JS and AP) assessed the 
quality, independently. In case of different opinion a discussion followed until 
consensus was reached. For each trial several quality items, as shown in Table 1, 
were noted. Based on these trial features the quality of each study was rated. If an 
article qualified for an item, one point was given. The maximum quality score was 
16. Next, the following data were collected on a standardized record form: number 
of patients, nature of the disease, interventions, nature of the study outcomes, 
methods for evaluating the optic disc and the visual field, mean pre- and post 
treatment IOP per trial arm or the change in IOP from baseline, and the incidence of 
glaucoma or its progression. 
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Table 1: Quality items included for the quality assessment, source of the quality item, and number of publica-
tions with a positive quality score per item in 10 trials identified in the systematic review 
 
Item 
code 
 
Source 
 
Quality item 
No. of 
publications scored 
‘yes’* 
A Delphi list15 Was the randomization procedure concealed? 5 
B Delphi list Were eligibility criteria specified? 9 
C Delphi list Was the patient blinded? 4 
D Delphi list Was the care provider blinded? 4 
E Delphi list Was the outcome assessor blinded? 8 
F Delphi list Were the groups similar at baseline regarding the 
most important prognostic indicators? 
8 
G Cochrane Collaboration  Was there a selective loss to follow-up? 3 
H Delphi list Did the analysis include an intention-to-treat analy-
sis? 
10 
I Cochrane Collaboration Were other interventions comparable? 4 
J Considered for Delphi list Is it unlikely that compliance may explain differences 
between groups? 
0 
K Delphi list Were point estimates and measures of variability 
presented for the primary outcome measures? 
9 
L Added by authors  Was the follow-up period comparable? 9 
M Added by authors Was there an explicit description of intervention? 10 
N Added by authors Was the outcome assessment properly described? 8 
O Added by authors Were side effects reported? 7 
P Considered for Delphi list Was calculation of statistical power reported after 
treatment allocation? 
6 
* complementary answers were ‘unknown’ or ‘no’ 
Data Analysis 
The outcome of interest was defined as the cumulative incidence of glaucoma or its 
progression. A relative risk per study was calculated: the incidence in the interven-
tion group divided by the incidence in the control group, with its 95% confidence 
interval. The relative risks of the individual studies were combined in a meta-
analysis and a pooled relative risk was calculated using a ‘random effects model’.16 
Heterogeneity was assessed by judging the forest plot and by the Q-test and I2 
statistic.17 To examine publication bias Egger’s measure of publication bias was 
calculated.18 
 
The interpretation of data from one study needs further clarification. In the Euro-
pean Glaucoma Prevention Study (EGPS) there was a major loss to follow-up and 
patients who reached a safety point (IOP > 35 mm Hg) were excluded from the 
trial. We assumed that patients lost to follow-up developed glaucoma according to 
the incidence of the group without treatment. Furthermore, because high IOP is 
often associated with conversion to glaucoma we considered patients who reached a 
safety endpoint as having developed glaucoma. 
 
A meta-regression analysis was used to determine the glaucoma risk reduction per 
mm Hg of IOP reduction achieved through therapy. For this purpose the logarithm 
of the relative risk was modeled, weighted by the inverse of its variance, dependent 
on the difference in the end IOP. This was defined for each study as the end IOP in 
the control group minus end IOP in the intervention group (mm Hg). 
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In a sensitivity analysis, the robustness of the findings to different assumptions was 
examined. Also the impact of an exclusion of trials of poorer quality on the out-
come of the meta-analysis was examined. The overall effect was calculated for the 
studies with a quality score of 10 points or more. An impact of an addition of a 
study with no treatment effect on the outcome of the meta-analysis was assessed by 
including a hypothetical study with 4000 patients and a relative risk of 1. Addition-
ally, meta-analyses were performed with different relative risk values for the EGPS 
study (the calculations of these values are given in Table 2). 
Results 
4109 articles were identified. After screening the articles by title and abstract 1422 
papers remained. From these finally, nine trials in OH patients and one trial in 
glaucoma patients met the inclusion criteria and were selected.8,9,19-26 (see Figure 1). 
Results from the OH trials were pooled in a meta-analysis. In Table 2 the basic 
characteristics of the selected studies and the quality score for each study are 
shown. Five OH trials and the glaucoma study had a score above 10 (maximum 
score was 16). These were also the largest and the most recent studies. There was 
no indication for significant heterogeneity between the studies (Q = 15.19 (P = 
0.085), I2 = 47%). Nor was there an indication for presence of a publication bias, 
the P value of Eager’s measure of publication bias was 0.31. Figure 2 gives the 
results of the meta-analysis. As seen in this figure, all individual studies in ocular 
hypertension showed a positive effect of IOP lowering by glaucoma medication on 
a reduction of the incidence rate of glaucoma. The calculated pooled relative risk is 
0.61 (95% CI 0.45-0.83). The 95% confidence intervals of the studies include the 
overall effect estimate. 
 
According to the meta-regression model there is a relationship between the differ-
ence in end IOP in the control group and the intervention group and the risk of 
conversion to glaucoma (see Figure 3). The relative risk of conversion to glaucoma 
decreases with an increase in difference in the achieved IOP reduction between the 
control group and the intervention group. With each mm Hg difference of the end 
IOP the relative risk of conversion to glaucoma decreases with 14%. 
 
The Early Manifest Glaucoma Trial (EMGT) showed that lowering the IOP is 
beneficial in slowing glaucoma progression. When the cumulative incidence was 
calculated after 48 months, the relative risk was 0.61 (95% CI 0.45-0.84). When 
calculations were made after a median follow-up of 6 years, the relative risk was 
0.73 (95% CI 0.57-0.92). 
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Figure 1: Flowchart of the selection of the studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity analysis 
The calculations of the overall effect in the meta-analysis by the random and fixed 
effects models showed no substantial difference. The pooled relative risk calculated 
by the ‘random effects model’ was 0.61 (95% CI 0.45-0.83) whereas by the ‘fixed 
effects model’ this was 0.65 (95% CI 0.54-0.78). When only studies with a quality 
score higher than 10 (points) were included, the pooled relative risk was 0.63 (95% 
Papers potentially to be included in the 
meta-analysis, screened by title, 
keywords and abstract (n = 1422) 
Papers retrieved for a detailed 
evaluation (n = 13) 
Trials included for the analysis (n = 10) 
(9 ocular hypertension trials and 1 
glaucoma trial) 
Not eligible (n = 1409) 
Main reasons: no randomised 
controlled trial; follow-up 
shorter than 6 months; no 
visual field or optic disc 
changes as an endpoint 
Trials excluded for the 
analysis (n = 3) 
Reasons: conversion to 
glaucoma not a primary 
outcome; no randomised 
trial; number of patients 
with progression not given 
(visual field deterioration 
expressed as a coefficient)  
Identified papers (n = 4109)  
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CI 0.43-0.90). Inclusion of a hypothetical study, showing no treatment effect, in the 
meta-analysis did not change its conclusions. When a hypothetical study with 4000 
patients, a relative risk 1, and an assumed glaucoma incidence of 10% was added, 
the pooled relative risk remained below 1, namely 0.80 (95% CI 0.71-0.92). Calcu-
lations of the overall effect with the higher value for the relative risk of the EGPS 
study did not influence the conclusions of the meta-analysis. An analysis with a 
0.93 value (see Table 2) gave a pooled relative risk of 0.62 (95% CI 0.44-0.87). The 
value of 0.77 (see Table 2) gave a pooled relative risk of 0.60 (95% CI 0.45-0.80). 
 
 
 
Figure 2: Meta-analysis of the relative risks of the nine ocular hypertension trials  
Forest plot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pooled relative risk: RR = 0.61 (95% CI 0.45-0.83); Q = 15.19, P = 0.085; I2 = 47%; p-publication bias 0.313 
The square and the horizontal line for each study correspond to the point estimate and a 95% confidence 
interval. The area of the square reflects the weight of the study in the meta-analysis. The solid vertical line 
through RR = 1 corresponds to no effect of treatment. The diamond represents the pooled relative risk with 
95% confidence interval. 
EGPS = European Glaucoma Prevention Study; OHTS = Ocular Hypertension Treatment Study 
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Figure 3: Meta-regression analysis of the relative risks of the nine ocular hypertension trials, carried out in the 
logarithmic domain, dependent on the end intraocular pressure (IOP) difference between the control and the 
intervention group 
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Discussion 
Our analysis shows that IOP lowering reduces the risk of glaucoma and also that a 
larger lowering of IOP is associated with a greater reduction of this risk. All studies 
included in the meta-analysis showed a beneficial effect of an IOP lowering ther-
apy. The computed pooled relative risk was 0.61 (95% CI 0.45-0.83). The relative 
risks were calculated from the cumulative incidence. All studies had a follow-up up 
to 5-6 years. The meta-regression model showed that the relative risk of conversion 
to glaucoma decreases by 14% with each mm Hg of IOP reduction achieved 
through therapy. 
 
The protective effect of pressure lowering treatment is consistent with the outcomes 
of a recently published meta-analysis performed by Maier et al.27 The authors of 
this study performed a meta-analysis of time to event data and the computed hazard 
ratio in this study is 0.56 (95% CI 0.39-0.81). However, Maier et al. included only 
five OH trials in their analysis. In the present meta-analysis four more OH studies 
were added including the second largest trial in ocular hypertension, the European 
Glaucoma Prevention Study, the results of which were only published in 2005. 
Three of the remaining four studies use fellow eye as a control.20,24,25 This was an 
exclusion criterion by Maier et al. In addition, in the present study the outcomes of 
the nine individual trials were used to carry out a meta-regression analysis to relate 
the size of IOP reduction to the effect on the conversion to glaucoma. 
 
The present systematic review is based on search of articles in the three most rele-
vant databases (Medline, Embase and Cochrane). The validity of the search is 
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corroborated by the search results of Maier et al., who identified the same articles. 
The meta-analysis was performed for the OH trials. We have identified one trial 
only which included glaucoma patients, the Early Manifest Glaucoma Trial. We did 
not search for normal pressure glaucoma, considering the possible different patho-
genesis of the normal- and high-pressure glaucoma, and a different therapy re-
sponse. It must be noted that a proportion of patients in the EMGT study had nor-
mal pressure glaucoma, however, the subgroup analysis of the patients showed a 
protective effect of IOP lowering particularly for those patients with an increased 
intraocular pressure.26 
 
The trial interventions were limited to the use of topical medication in OH patients 
and a combination of topical medication with laser trabeculoplasty in glaucoma 
patients. As expected, surgery was not included in any of the trials, because it is not 
a primary treatment option for ocular hypertension or early glaucoma. We did not 
find any randomized controlled trials comparing treatment with no treatment con-
ducted in patients with advanced glaucoma. This is to be expected, since avoiding 
treatment in such patients would be ethically inappropriate. 
 
The OH studies with the most extreme positive outcomes, with the lowest relative 
risks, are the oldest studies with the lowest quality scores and with least weight in 
the meta-analysis. In three studies the relative risk was higher than the pooled 
estimate, but still lower than 1. The study with a relative risk closest to 1 (done by 
Schulzer et al.) scored 9 quality points. It included 143 patients. The Ocular Hyper-
tension Treatment Study (OHTS) and the European Glaucoma Prevention Study are 
the studies with most weight in the meta-analysis. These studies included 1636 and 
1077 patients. The OHTS study is the largest study, which showed the effectiveness 
of reducing the IOP with topical medication in delaying or preventing the onset of 
POAG with statistical significance (p<0.0001). The EGPS study failed to do so. 
This study showed somewhat unexpected results. The difference in IOP reduction 
between the treatment and control group was only 1 mm Hg during the course of 
the study and the IOP dropped substantially in the control group. As pointed out by 
Dr. Quigley, three significant differences with the OHTS study may explain the 
failure of the EGPS study to find a therapy benefit: (1) the use of dorzolamide 
therapy alone, regardless of IOP lowering with placebo control; (2) a major regres-
sion to the mean in IOP at 6 months; (3) selective loss to follow-up of persons with 
higher IOP.28 It should be noted, that the observed, even though non-significant risk 
reduction in this study, is consistent with the expected effect of a 1 mm Hg differ-
ence in IOP, according to our meta-regression model. 
 
By viewing the results of the individual studies, most striking are the outcomes of 
the trial done by Schulzer et al.. In this study, in spite of an end IOP difference of 
4.5 mm Hg, the difference in the glaucoma development between the two trial arms 
was small (RR = 0.93 (95% CI 0.53-1.64)). It must be noted that glaucoma inci-
dence was very high in this study (see Table 2). This could be explained by the fact 
that the population was at high risk of developing glaucoma. From the included 
patients 31% had a positive family history of glaucoma, 20% had a baseline entry 
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pressure of 30 mm Hg or greater, and 29% had a cup-to-disc ratio of 0.5 or greater 
at entry. The high-risk patients were represented equally in the intervention and 
control group. Moreover, the mean achieved IOP level in the treated group was 21.8 
mm Hg, which is rather high for the high-risk patients. This study scored 9 quality 
points. When a separation of the studies into two groups with a quality score less 
than 10 points and 10 points or more was introduced in the regression model, this 
did not significantly change the outcomes of the meta-regression (p-interaction = 
0.770). 
 
The Early Manifest Glaucoma Trial showed a protective effect of immediate treat-
ment, compared with no initial treatment or later treatment, in patients with early 
glaucoma. This trial included newly diagnosed and previously untreated open-angle 
glaucoma patients with early visual field loss. When the cumulative incidence was 
calculated after 48 months, the relative risk was 0.61 (95% CI 0.45-0.84). When 
calculations were made after a median follow-up of 6 years, the relative risk was 
0.73 (95% CI 0.57-0.92). The authors of the study calculated patient-based risk of 
progression using a Cox proportional hazard regression model. The calculated 
hazard ratio after 6 years was 0.50 (95% CI 0.35-0.71). In the trial an initial ran-
domization to treatment or no treatment was maintained only as long as progression 
did not occur. The study does not include long-term follow-up of untreated patients 
beyond EMGT progression. The EMGT multivariate analyses showed that the risk 
decreased about 10% with each millimeter mercury of IOP reduction from baseline, 
which seems consistent with the results of our meta-regression.29 
Conclusion 
There is sufficient scientific evidence that topical hypotensive therapy reduces the 
risk of conversion to glaucoma in ocular hypertension and a progression of visual 
field loss in early glaucoma. The evidence is provided by a number of well-
conducted randomized controlled trials. Moreover, the risk of conversion to glau-
coma in patients with ocular hypertension decreases with approximately 14% per 
each mm Hg of extra IOP reduction. 
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Abstract 
Objective: To establish the effectiveness of early detection and treatment of ocular 
hypertension (OH) and primary open-angle glaucoma (POAG) in the ophthalmic 
practice on the prevention of glaucoma blindness. 
Design: A case-referent study. 
Methods: Cases are patients who became blind due to glaucoma in at least one eye. 
Referents are patients with an exudative form of age-related macular degeneration 
(AMD) and a Snellen visual acuity < 0.3 in at least one eye. An exposure to tests by 
which OH and glaucoma can be detected (tonometry and ophthalmoscopy) prior to 
the diagnosis was retrieved from the medical charts of the cases and referents. Two 
glaucoma specialists did the retrieval of data from the medical records, independent 
of each other and unaware whether the record was of a case or a referent. They were 
asked to give the amount of certainty with which they judged whether an examina-
tion could be considered a ‘screening’ moment and thus not based on patients 
symptoms on a six point scale from ‘certainly’ to ‘certainly not’. If early detection 
and treatment is effective in preventing glaucoma blindness it is to be expected that 
the frequency of these examinations is lower among cases compared to referents 
that represent the frequency of such testing in the general population. The relative 
risk, expressing the effect of early detection on glaucoma-related blindness, ad-
justed for potential confounders was estimated in a logistic regression analysis. 
Diabetes mellitus, hypertension, myopia, family history of glaucoma, year of the 
diagnosis and age were taken as potential confounders. 
Results: Fewer cases than referents were screened by ophthalmologists for ocular 
hypertension and early glaucoma within 20 years prior to their diagnosis. The crude 
relative risk (RR) is 0.57 (90% confidence interval 0.31-1.05), when adjusted for 
potential confounders the RR is 0.46 (90% confidence interval 0.22-1.00). 
Conclusion: The application of tonometry and ophthalmoscopy as screening tests 
for early detection of ocular hypertension and glaucoma by ophthalmologists is 
likely to lead to a reduction of glaucoma blindness.  
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Introduction 
Primary open-angle glaucoma (POAG) is a chronic optic neuropathy in which the 
progressive loss of the retinal ganglion cells leads to characteristic structural 
changes at the head of the optic nerve and to functional loss to the visual field.1 This 
process is insidious and takes place over a relatively long time period. In many 
patients there are no noticeable symptoms until patients lose their central vision. An 
elevated intraocular pressure (IOP) defines ocular hypertension (OH) and is a major 
risk factor for a conversion to glaucoma and a prognostic factor for the occurrence 
of visual field loss. Treatment is aimed to lower the IOP. 
 
In spite of the fact that glaucoma is an important public health problem there is no 
screening programme for OH and POAG.2 However, early detection in the form of 
case-finding takes place in ophthalmologic practice. The efficacy of early detection 
by case-finding and consequent treatment to prevent glaucoma blindness has not yet 
been investigated. Due to the need of a large sample size, long follow-up and 
ethical considerations, a randomized clinical trial or a prospective cohort study are 
not well suited for this purpose. Another type of epidemiological study, a case-
referent study, can give an estimation of the effect of screening or case-finding if 
the number of screening examinations received prior to the date of diagnosis for 
cases and referents are assessed.3 This type of study allows a direct estimation of 
the effect size.4 A case-referent study is relatively easy to conduct with fewer costs 
since fewer patients need to be included and there is no need for a follow-up since 
cases already have reached the outcome that one wishes to prevent with screening 
or case-finding. In other fields of medicine case-referent studies have been used to 
evaluate the efficacy of screening programmes on the occurrence of death.5,6 
 
Glaucoma meets many criteria for screening.2 One of the criteria is that the targeted 
disease has a pre-clinical stage which is detectable by suitable screening tests. A 
further prerequisite is that there are effective treatments that reduce the progression 
to the end stage of the disease. An elevated IOP can be detected by tonometry.7 The 
early glaucomatous structural changes of the optic nerve head can be detected by 
ophthalmoscopy before significant visual field loss occurs.8 There are effective 
treatments to lower the intra-ocular pressure that prevent a conversion to glaucoma 
or its progression.9-11 
 
If early detection and a subsequent application of an efficacious therapy can reduce 
the conversion or progression rate of the disease, then it is likely that testing for 
early detection is beneficial for the prevention of glaucoma-related blindness. In 
this paper a case-referent study is presented in which the effect of early detection of 
OH and POAG by case-finding in ophthalmologic practice on the occurrence of 
glaucoma blindness is estimated. 
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Methods 
Study setting 
Cases and referents were ophthalmic patients treated at the University Hospital 
Maastricht. The hospital research ethics board (REB) approved the conduct of this 
study. All patients were informed about the study and consented to their enrolment. 
The study adhered to the tenets of the Declaration of Helsinki. 
Identification of cases and referents 
For identifying potential cases first all consecutive patients who underwent a 10-2 
Humphrey visual field testing (Humphrey perimetry, Carl Zeiss Meditec, Dublin 
CA) during two years, from 01-01-2000 until 19-02-2002, at the University Hospi-
tal Maastricht were selected. The print-outs of the visual field and basic patient 
information were abstracted directly from the Humphrey hardware by the use of a 
software program PeriData (PeriData Software GmbH). Next, patients were se-
lected who met the inclusion criteria. Cases had to meet the following criteria: (1) 
diagnosis primary open-angle glaucoma (2) functioning visual field in at least one 
eye restricted to 10 degrees (3) resident of the chosen region (4) born between 
1920-1940 (5) treated for glaucoma at the University Hospital Maastricht. The final 
selection of the study participants was based on patients’ approval with the partici-
pation in the study and on the availability of the data. First, the medical charts of all 
potential participants were collected. If patients were referred from another hospital, 
a copy of their medical record was requested. If a record could not be found, if the 
notes were incomplete, or if the diagnosis preceded the first date on the medical 
chart patients were not included. 
 
Referents had to meet the following criteria: (1) a diagnosis exudative form of age 
related macular degeneration (AMD) (2) visual acuity < 0.3 due to MD in at least 
one eye (3) resident of the chosen region (4) born between 1920-1940 (5) treated 
for macular degeneration at the University Hospital Maastricht. First, all consecu-
tive patients who underwent fluorescein angiography (FAG) at the University 
Hospital Maastricht from 01-01-1997 until 31-12-2002 were identified. Thereafter, 
the same procedure as described by the cases was used for the final selection of 
referents. 
 
Patients were initially approached by mail. The letters, printed in large print, in 
which the nature of the study was explained, were signed by the treating ophthal-
mologist. Patients were asked to sign their approval of enrollment in the study. 
Patients who did not respond received a reminder. Patients who did not respond to 
the reminder were approached by phone. 
Data collection 
An exposure to tests for early detection prior to the diagnosis POAG or AMD was 
ascertained by reviewing the medical records of the study participants. The tests for 
detection were defined as tonometry and ophthalmoscopy. A diagnosis OH was 
considered detection for POAG patients. If an IOP of 22 mm Hg or more was found 
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the date of this finding was taken as the date of the diagnosis. Testing had to be 
performed in a time period when progression in glaucoma patients could have been 
stopped or slowed down by treatment. Testing had to take place within 20 years 
preceding the date of the diagnosis. For the cases testing was not considered a 
‘screening’ moment if the tests were performed due to complaints associated with 
glaucoma or if it took place within one year before the occurrence of blindness. For 
the referents testing was not considered a ‘screening’ moment if the tests were 
performed due to complaints of AMD. For each participant the information on 
medical history and notes made during the outpatients visits were photocopied from 
the charts. Two glaucoma specialists (CW and HB) were asked to review the photo-
copies and state whether an examination could be considered as screening or was 
based on patient’s symptoms. The judgment was scored on a six point ordinal scale: 
‘certainly’; ‘very probably’; ‘probably’; ‘probably not’; ‘very probably not’; ‘cer-
tainly not’. They were kept unaware of whether a participant was a case or a refer-
ent. 
 
Further patient data that were retrieved from the medical charts were: age, sex, year 
of the diagnosis (POAG or AMD) and myopia (spherical equivalent < - 4.0 D). In 
addition, presence of diabetes mellitus, hypertension, and a positive family history 
of glaucoma were assessed by means of a questionnaire. This questionnaire was 
sent by mail, printed in large letters. 
Data analysis 
The effect of early detection of OH and POAG on glaucoma blindness was ex-
pressed as a relative risk (RR). The ratio of the frequency of testing for OH and 
POAG prior to the diagnosis POAG among the cases was divided by the ratio of the 
frequency of such testing prior to the diagnosis AMD among the referents. A RR 
below 1 would then indicate that the testing for early detection of OH and POAG is 
less likely among the cases. Next, the calculated RR was adjusted for potential 
confounders in a logistic regression model. The following variables were taken as 
potential confounders: diabetes mellitus, hypertension, myopia, family history of 
glaucoma, year of the diagnosis and age. For the analyses the judgement of the 
ophthalmologist, whether the performed testing could be considered as screening, 
which was more conservative (leading to a RR closest to 1) was chosen. The analy-
ses were performed for two different cut-off points on the ordinal scale. First the 
options ‘certainly’, ‘very probably’, and ‘probably’ were considered positive and 
then only the options ‘certainly’ and ‘very probably’. 
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Table 1: Number of potential cases and referents, reasons for exclusion and the final number of the study 
participants 
 Cases Referents 
Patients considered for the study  
(based on visual field or fluorescein angiography) 151 252 
Patients who met the inclusion criteria  83 186 
Reasons for no participation in the study:   
      - no informed consent 17 41 
      - no additional information from a referring hospital 18 9 
      - incomplete additional information from a referring hospital 3 4 
      - untraceable medical chart - 5 
      - diagnosis before the history of the medical chart 4 3 
      - diagnosis of glaucoma prior to the diagnosis of MD - 14 
Total number of study participants  41 110 
 
 
Table 2: Baseline characteristics of cases and referents 
 Cases 
(n = 41) 
Referents 
(n = 110) 
Mean age at diagnosis (years ± SD)) 63.5 (±5.9) 70.0 (±5.0) 
Men 17 (41 %) 57 (46 %) 
Myopia 26 (63 %) 48 (44 %) 
Family history of glaucoma 7 (17 %) 14 (13 %) 
Diabetes mellitus 7 (17 %) 15 (14 %) 
Hypertension 7 (17 %) 21 (19 %) 
The results 
In Table 1 an overview is given of number of patients initially considered for the 
study, the reasons for non-inclusion and the final number of patients who were 
enrolled. Finally, 41 cases and 110 referents were included. The baseline character-
istics of these patients are given in Table 2. Cases were younger when diagnosed, 
with a mean age of 63 years, compared to 70 years in referents. The mean year of 
the diagnosis was 1992 (SD ± 6.2), among the cases and 1997 (SD ± 3.8) among the 
referents. A history of tests for early detection by tonometry and/or ophthalmoscopy 
was less common among cases, namely 16 (39%), than among referents, 58 (53%) 
(p = 0.13). The results of the analysis are given in Table 3. The crude effect meas-
ure (not adjusted for possible confounding) was 0.57 (90% confidence interval 
0.31-1.05). After adjustment for all listed potential confounders in a logistic regres-
sion model the RR became 0.46 (90% confidence interval 0.22-1.00). When in the 
analysis the cut-off point for the judgement whether testing could be considered a 
‘screening’ moment was shifted and only the options ‘certainly’ and ‘very proba-
bly’ were taken as positive, then the unadjusted RR became 0.40 (90% confidence 
interval 0.21-0.74), and the RR adjusted for all potential confounders was 0.34 
(90% confidence interval 0.16-0.72). 
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Table 3: Results of the case-referent study - relative risk of the application of the examinations for early 
detection of glaucoma among the cases and referents, unadjusted and adjusted for potential confounders, for 
two different cut-off points of the certainty that the performed examinations were applied as an early detection 
 
Crude effect 
Relative risk (RR) 
cut-off point 1** 
Relative risk (RR) 
cut-off point 2*** 
 
Unadjusted for confounding 
 
0.57 (90% CI 0.31-1.05) 
 
0.40 (90% CI 0.21-0.74) 
   
Adjusted for the listed potential confounders* 0.46 (90% CI 0.22-1.00) 0.34 (90% CI 0.16-0.72) 
* potential confounders: diabetes mellitus, systemic hypertension, myopia, family history of glaucoma, year of 
the diagnosis, age 
** options ‘certainly’, ‘very probably’, and ‘probably’ taken for the confirmation that testing was applied as 
an early detection 
*** options ‘certainly’ and ‘very probably’ taken for the confirmation that testing was applied as an early 
detection 
Discussion 
In this paper a case-referent study is presented which was designed to investigate if 
early detection of OH and POAG by means of case-finding by the ophthalmologist 
is beneficial for the prevention of glaucoma-related blindness. The relative risk 
adjusted for possible confounding is 0.46 (90% confidence interval 0.22-1.00). 
When for more certainty was chosen in whether testing could be considered a 
‘screening moment’, the relative risk, after adjustments for confounding, became 
0.34 (90% confidence interval 0.16-0.72). This suggests that early detection of OH 
and POAG by means of case-finding by the ophthalmologist reduces the risk of 
glaucoma blindness to about one half or more of the risk when no case-finding is 
done. 
 
The calculation of the relative risk is based on a proportion of individuals who 
underwent testing by tonometry and/or ophthalmoscopy prior to their diagnosis, not 
based on patient’s symptoms. The argumentation why this should have an impact 
on the occurrence of blindness is that when a performance of these tests by which 
OH and early POAG can be detected is not based on the disease symptoms, one can 
assume that the disease is diagnosed and treated in an early stage. If treatment of 
OH and early glaucoma is effective in blindness prevention then patients diagnosed 
in time will not progress to blindness. To obtain a reasonable estimate of the true 
effect it is essential that the proportion of individuals who underwent tonometry and 
ophthalmoscopy among the referents is a valid estimate of the proportion of indi-
viduals with these examinations in the general population from which the blind 
glaucoma patients come. 
 
The choice of the referents is fundamental and has to fulfill two criteria.12 Firstly, 
the referents must come from the same general population as the cases. For this 
reason referents were chosen from the same hospital and the same region as the 
cases. It is plausible that if a referent would have become a glaucoma patient he 
would have been included in the study as a case because he would have been treated 
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in the same hospital. Secondly, the referents’ disease and disease stage should not 
be related to the examinations under study. Blindness due to exudative macular 
degeneration is not associated with the tests for early detection of glaucoma. Al-
though AMD can be detected by ophthalmoscopy, this does not influence the course 
of the disease and the occurrence of blindness since there is, or until recently there 
was not, an effective treatment for it. To prevent bias the testing was only consid-
ered a ‘screening’ moment if the tests were not related to the symptoms of AMD 
that may have led these patients to visit an ophthalmologist. 
 
Another precaution taken to minimize bias was blinding of the ophthalmologists 
(who had to indicate whether testing was done on indication or not) to whether a 
patient was a case or a referent. 
 
The confounders for which the crude effect has been adjusted, i.e. diabetes mellitus, 
hypertension, myopia, family history of glaucoma and age are (potential) risk 
factors for glaucoma. Additonally, year of the diagnosis and also age may be related 
to the aspect of time. Cases have been diagnosed earlier than referents. This is to be 
expected because the rate of blindness is slower in patients with glaucoma than in 
patients with AMD. The time period may be associated with detection, because in 
the past people used to visit an ophthalmologist more often than nowadays e.g. for a 
prescription of spectacles. Age may be associated with detection because older 
people visit an ophthalmologist more often than younger persons. 
Conclusions 
The results of the case-referent study show that fewer blind glaucoma patients 
underwent tests for early detection of ocular hypertension and glaucoma than 
referents, which represent such testing in the general population. This supports the 
hypothesis that early detection and treatment has a positive effect on the prevention 
of glaucoma blindness. The outcomes of the present study emphasize the need for 
the assessment of IOP and an optic nerve examination in each patient visiting an 
ophthalmologist. 
References 
1 Liesegang TJ, Skuta GL, Cantor LB. Glaucoma. Basic and Clinical Science Course. American Academy 
of Ophthalmology 2003. 
2 Harasymowycz P, Kamdeu Fansi A, Papamatheakis D. Screening for primary open-angle glaucoma in the 
developed world: are we there yet? Canadian journal of ophthalmology; Journal canadien 
d’ophtalmologie 2005;40(4):477-86. 
3 Hosek RS, Flanders WD, Sasco AJ. Bias in case-control studies of screening effectiveness. American 
journal of epidemiology 1996;143(2):193-201. 
4 Miettinen OS. Estimability and estimation in case-referent studies. American journal of epidemiology 
1976;103(2):226-235. 
5 Sasco AJ, Day NE, Walter SD. Case-control studies for the evaluation of screening. Journal of chronic 
diseases 1986;39(5):399-405. 
The effect of early detection of OH and POAG on blindness 
 43 
6 Weiss NS, McKnight B, Stevens NG. Approaches to the analysis of case-control studies of the efficacy of 
screening for cancer. American journal of epidemiology 1992;135(7):817-23. 
7 American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern. Primary Open-Angle 
Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2005. Available at: 
www.aao.org/ppp. 
8 Zeyen G, Caprioli J. Progression of Disc and Field Damage in Early Glaucoma. Archives of Ophthalmol-
ogy. 1993;111: 62-65. 
9 Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized 
trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-
angle glaucoma. Archives of ophthalmology 2002; 120: 701-713. 
10 Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma 
progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology 2002; 120: 
1268-1279. 
11 Kamal D, Garway-Heath D, Ruben S, et al. Results of the betaxolol versus placebo treatment trial in 
ocular hypertension. Graefe’s archive for clinical and experimental ophthalmology 2003; 241: 196-203. 
12 Miettinen OS. The “case-control” study: valid selection of subjects. Journal of chronic diseases 
1985;38(7):543-48. 
 45 
4. 
Cost-effectiveness of early detection and 
treatment of ocular hypertension and primary 
open-angle glaucoma by the ophthalmologist 
Andrea Peeters 1 
Jan S.A.G. Schouten 1 
Carroll A.B. Webers 1 
Martin H. Prins 2,3 
Fred Hendrikse 1 
Hans L. Severens 3,4 
1 Department of Ophthalmology, Maastricht University Hospital, Maastricht, The Netherlands 
2 Department of Epidemiology, Maastricht University, Maastricht, The Netherlands 
3 Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht Univer-
sity Hospital, Maastricht, The Netherlands 
4 Department of Health Organisation, Policy and Economics, Maastricht University, The Nether-
lands 
 
  
 
 
 
 
 
 
Eye advance online publication, 24 November 2006; doi:10.1038/sj.eye.6702637 
Chapter 4 
 46
 
 
 
 
 
 
 
Abstract 
Purpose: To determine the most cost-effective case-finding strategy for the oph-
thalmologist to detect and treat ocular hypertension (OH) and primary open-angle 
glaucoma (POAG) at an early stage to prevent blindness. 
Design: A Markov cost-effectiveness simulation model. 
Methods: Three case-finding strategies are analyzed and compared. The simulated 
cohort consists of all initial patients of at least 40 years old visiting an ophthalmic 
practice. All patients undergo ophthalmoscopy, but tonometry is routinely per-
formed to: (1) all initial patients, (2) high-risk patients only, or (3) no one. The 
population characteristics are based on data of 1 000 initial patients. Transition 
probabilities are taken from the literature. The (direct) costs of diagnosis and treat-
ment represent those for The Netherlands. The time-horizon of the model is 20 
years. An annual discount rate of 4% is used. 
Main outcome measures: Costs, proportion of patients becoming blind, years of 
blindness. 
Results: The costliest strategy (1) leads to least blindness. The incremental cost-
effectiveness ratio, which shows extra costs per year of vision saved in comparison 
to the cheapest strategy (3), is lower for strategy (1) than for strategy (2). It amounts 
to € 1 707, not including extra costs due to blindness (e.g. associated with the use of 
disability facilities). When such costs exceed € 1 707 per patient per year, which is 
most likely, then strategy (1) becomes cost saving. 
Conclusions: It is most cost-effective to routinely perform tonometry to all initial 
ophthalmic patients to prevent blindness due to glaucoma.  
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Introduction 
Primary open angle glaucoma (POAG) is an important public health problem, being 
the second leading cause of bilateral blindness worldwide.1 It is characterized by 
progressive optic nerve atrophy leading to visual field damage and possibly blind-
ness. The natural history of POAG is though variable; some people develop signifi-
cant visual problems, while others do not.2 An elevated intraocular pressure (IOP) 
defines ocular hypertension (OH) and is a major risk factor for POAG. Through 
IOP lowering treatment the risk of glaucoma and its progression can be reduced.3,4 
 
In the past it has often been suggested that a screening program should be set up, 
but because of high costs and unknown effectiveness it has never been systemati-
cally introduced.5 In the last two decades new technologies have been introduced 
that permit earlier detection of structural and functional damage due to glaucoma. 
New treatments, such as hypotensive lipids and selective laser trabeculoplasty, 
allow for safer and more effective IOP reduction. Several well conducted clinical 
trials showed the effectiveness of treatment.3,4 These new developments, and a 
possibly increasing prevalence of POAG due to aging, bring along the necessity to 
re-evaluate screening.6 However, the feasibility and efficacy of a screening program 
still can be questioned. Only recently the US Preventive Services Task Force con-
cluded that there is still insufficient evidence to recommend for or against a screen-
ing program for glaucoma.7,8 
 
An alternative for screening to discover and treat OH and POAG at an early stage is 
case-finding among patients visiting an ophthalmologist. The advantages compared 
to screening in the general population are the use of an existing infrastructure, the 
high probability for discovery by means of a complete ophthalmic examination and 
the direct initiation of treatment without loss to follow-up. Moreover, the preva-
lence of OH, POAG, and risk factors for glaucoma, is higher among patients visit-
ing an ophthalmologist than in the general population. 
 
In many countries ophthalmologists routinely apply strategies to detect OH and 
POAG. However, the effect of these strategies to prevent glaucoma blindness is 
unknown. The cost-effectiveness is unknown as well. This study aims to investigate 
the effects, costs, and cost-effectiveness of different case-finding strategies that can 
be applied by an ophthalmologist in daily practice to detect and treat OH and 
POAG at an early stage to prevent glaucoma blindness. 
Method 
Three case-finding strategies, which differ with respect to the group of patients 
routinely receiving tonometry, are analyzed and compared using a Markov cost-
effectiveness simulation model. In the model all initial ophthalmic patients undergo 
ophthalmoscopy to detect a glaucomatous optic nerve, but the three strategies differ 
by whether tonometry is routinely performed to: (1) all initial patients, (2) high-risk 
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patients only, or (3) no one. In case of positive results of testing with ophthalmo-
scopy and/or tonometry, perimetry is performed to complete the assessment of the 
correct diagnosis. These different diagnostic strategies lead to different proportions 
of patients being diagnosed and treated for OH or POAG. The long-term conse-
quences of these three strategies are then evaluated. 
 
The population characteristics are based on data gathered from the charts of 1 000 
initial patients visiting an ophthalmic practice. The transition probabilities are taken 
from the literature. The (direct) costs of diagnosis and treatment represent those for 
The Netherlands. The time-horizon of the model is 20 years and an annual discount 
rate of 4% is used. The analysis is performed from a societal perspective. 
The Model 
It is modeled that a cohort of initial patients visiting an ophthalmologist, having a 
certain prevalence of OH and POAG, undergoes testing to detect these disorders. 
The use of the diagnostic tests is strategy dependent, as described above, and so per 
strategy different proportions of patients are specified for observation, treatment, or 
discharge. Subsequently a 20-year follow-up is modeled, while the progression of 
patients returning for regular visits, but also that of the discharged patients is being 
tracked. Per strategy blindness due to glaucoma is determined and the correspond-
ing costs are computed. 
 
The cohort simulated in the model corresponds to initial patients of at least 40 years 
old visiting an ophthalmic practice. In the Netherlands the general practitioner 
refers the majority of such patients. The age and sex distribution, and the prevalence 
of OH and POAG are jointly taken into account. In the model the high-risk group is 
defined to consist of patients reporting a positive family history of glaucoma. Such 
patients have an increased risk of having glaucoma.9,10 
 
The model consists of two parts. Part one models the diagnostic process; part two 
models the disease progression over time. In part one, the known sensitivity and 
specificity of ophthalmoscopy and tonometry are used to calculate proportions of 
patients receiving the diagnosis OH or POAG for each strategy. This leads to a 
strategy dependent distribution of the patient cohort over the set of health states. 
These health states are defined by the true condition of a patient, by the obtained 
diagnosis and by the assigned therapy (see Figure 1). The therapy assignment 
corresponds to the clinical practice, where IOP level, the presence of risk factors, 
and severity of the disease play a role. Patients diagnosed as OH are either put 
under observation or given medical treatment with monotherapy. In the strategy 
‘tonometry all’ 50% of the OH patients starts medication directly after the diagnosis 
is made. The rest is kept under observation and receives treatment only if conver-
sion to POAG occurs. In the strategy ‘tonometry high-risk group’ all patients 
diagnosed as OH are at risk and therefore require medication. POAG patients start 
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therapy with monotherapy in all strategies; a small proportion undergoes laser or 
surgery directly. Missed OH and POAG patients are discharged. 
 
In part two of the model transitions between health states can take place. Here the 
development of OH in normotensives, the development of POAG from OH, and the 
progression of POAG to blindness is modeled. Also, undiagnosed patients are 
tracked and can be rediscovered. A distinction is made between patients completely 
discharged and patients still visiting the ophthalmologist regularly for some other 
ophthalmic condition. The latter group of patients has a higher chance of 
OH/POAG detection. For patients under therapy every 6 months an outpatient visit 
is modeled to take place and the proportion of patients showing progression is 
modeled to undergo a therapy switch. The therapy sequence is based on recommen-
dations of the American Academy of Ophthalmology; its chronological order is 
monotherapy, combination therapy, laser, and surgery.11 The end stage of the dis-
ease is blindness. Patients under treatment develop blindness only after surgery, 
when there are no further treatment possibilities. Discharged patients can also 
eventually develop blindness without treatment. Patients who become blind con-
tinue to use combination therapy and to visit an ophthalmologist once in two years. 
The false positives, patients unjustly positively diagnosed, continue to use mono-
therapy medication. 
 
The model is built and analyzed using the software package ‘Decision Analysis by 
TreeAge’ (Data), version 3.5. It has the structure of a Markov model and it has a 
time horizon of 20 years, consisting of 40 cycles of 6 months each. This choice of 
cycle length reflects the common time between the consecutive outpatient visits of 
the glaucoma patients. The diagnostic process is implemented as the first cycle 
only, the disease progression over time involves the other cycles. At the end of each 
cycle transitions between the health states take place. These transitions include age 
and sex dependent survival probabilities, probabilities concerning the discovery of 
undiagnosed patients, and the probabilities related to the development or progres-
sion of OH and POAG. These probabilities are independent of the three strategies 
being evaluated. 
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Cost assignment 
The direct medical costs are assigned as once-only costs and state dependent costs. 
The once-only costs are the costs of the diagnostic process and the costs for laser 
treatment and surgery. The state dependent costs are the costs of outpatient visits 
and medication. These costs are assigned to the health states and reflect the treat-
ment requirements related to 6 months of treatment of a particular state. The costs 
for diagnosis apply to all patients. The costs for treatment apply to diagnosed 
patients only. 
Outcomes 
The outcomes of the analysis concern: 1) costs, 2) proportion of patients becoming 
blind, 3) years of blindness. 
The health state ‘dead’ (not shown) can be entered from all other states. 
After the diagnosis was made, in part one of the model, all health states 
except ‘blind’ and ‘dead’ can be entered. The shown scheme is a 
simplified reproduction of the model. In the model a distinction is 
namely made between undiscovered patients completely discharged and 
patients still visiting the ophthalmologist regularly for some other 
ophthalmic condition. A distinction is also made in the form of medica-
tion, namely monotherapy or combination therapy. Another health state, 
not shown, is ‘false positives on monotherapy’. 
Figure 1: Part two of the simulation model: transitions among the health states 
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The Data 
The data and their sources are presented in Tables 1-3. The age distribution and the 
OH/POAG prevalence for the population have been determined from the charts of 
1 000 initial patients, consecutively visiting a general ophthalmic practice in Maas-
tricht (Medisch Centrum Maastricht Annadal - MCMA), starting from January 
1999.12 The global characteristics of the data are consistent with the indications 
from the literature.13-15 The values for sensitivity and specificity of the diagnostic 
tests were taken from the literature. The starting therapy assignment for discovered 
patients is consistent with the opinion of the glaucoma specialists, the recommenda-
tions of the American Academy of Ophthalmology and the European Glaucoma 
Society.11,16 In part two of the model the 6 months transition probabilities are 
calculated from the yearly transition probabilities, which are obtained as follows. 
The age and sex dependent survival probabilities are taken from data provided by 
the Dutch Central Bureau for Statistics (CBS).17 The modeled disease progression is 
based on the literature, mainly on the long-term follow-up studies and on therapy 
trials.3,18-37 The unit prices related to the outpatient visits, laser trabeculoplasty and 
surgery are as determined at the University Hospital Maastricht. This was done 
according to the micro costing method.38 The prices of medical drugs represent the 
prices in the Netherlands (incl. VAT). The prices of monotherapy and combination 
therapy are based on the average use of the individual drugs in the Netherlands, 
combining up to three drugs in the combination therapy. The frequency of the 
health care use is modeled in accordance with the specialists’ opinion and the 
recommendations of the American Academy of Ophthalmology. The costs due to 
blindness in connection with the usage of disability facilities in the Netherlands 
could not be retrieved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 52
Table 1: Parameters used in the simulation model 
Parameter Lower bound Baseline Upper bound Source  
 
A. Proportions 
     
Se tonometrya 0.90 1 - 54-56 
Se ophthalmoscopy 0.60 0.80 1 5,57-61 
Sp tonometry 0.90 1 - 54-56 
Sp ophthalmoscopy 0.80 0.90 1 5,57-61 
Screen positive OHb     5,57-61 
   strategy (1) 0.91 1 -  
   strategy (2) 0.20 0.28 0.36  
   strategy (3) 0 0.10 0.20  
Screen positive POAGb    5,57-61 
   strategy (1) 0.96 1 -  
   strategy (2) 0.67 0.84 1  
   strategy (3) 0.60 0.80 1  
Screen positive ‘normal’b    5,57-61 
   strategy (1) - 0 0.05  
   strategy (2) - 0 0.012  
   strategy (3) - 0 0.01  
Discovered OH patients with check-up only    Estimate 
   strategy (1) 0.40 0.50 0.60  
   strategy (2) - 0 -  
   strategy (3) 0.40 0.50 0.60  
Patients with regular visits due to other condition  0.4 0.5 0.7 14, clinical data
POAG patients with direct laser assignment 0 0.02 0.05 39, estimate 
POAG patients with direct surgery assignment 0 0.02 0.05 39, estimate 
 
B. Yearly probability estimates 
     
Discovery of OH in ‘visitors’    5,57-61 
   strategy (1) - 0.95 -  
   strategy (2) - 0.10 -  
   strategy (3) - 0.10 -  
Discovery of OH in ‘discharged’c    62, clinical data
   strategy (1) 0.01 0.05 0.10  
   strategy (2) 0.0028 0.014 0.028  
   strategy (3) 0.001 0.005 0.01  
Discovery of POAG in ‘discharged’c    62, clinical data
   strategy (1) 0.01 0.05 0.10  
   strategy (2) 0.0084 0.042 0.084  
   strategy (3) 0.008 0.04 0.08  
OH development in discharged ‘normals’ 0.002 0.003 0.006 18,19 
POAG development in discharged OH patients 0.02 0.05 0.10 3,18,20-24 
Blindness development in untreated POAG patients 0.05 0.133 0.2 5,63,64 
POAG development in OH patients with check-up only 0.015 0.02 0.07 3,23 
Switch to combination therapy in OH patients on monotherapy  0.08 0.095 0.11 3,25,26 
Switch to combination therapy in POAG patients on monotherapy 0.20 0.213 0.25 25-27 
POAG development in OH patients on combination therapy  0.037 0.054 0.089 3,24,28 
Switch to laser in POAG patients on combination therapy 0.32 0.49 0.74 25,39 
Success laser 0-1 years after the interventiond 0.65 0.70 0.75 29-33 
Success laser >1 year after the interventiond 0.85 0.87 0.90 29-33 
Success surgery 0-5 years after the interventione - 0.94 - 34-37 
Success surgery 5-10 years after the interventione - 0.95 - 34-37 
Success surgery >10 years after the interventione - 0.975 - 34-37 
Discovery of POAG in ‘visitors’ - 0.95 - 5,60,61 
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a Values reflect IOP measurement by the Goldmann applanation tonometer (golden standard) to diagnose 
patients with IOP > 21 mm Hg. 
b Per strategy the proportions of the correct diagnoses have been calculated, using the following assumption. 
In case of a positive outcome of at least one of the performed tests a patient undergoes further examinations 
and will be correctly diagnosed within the first 6 months. Values for perimetry were not required for the 
calculations, even if perimetry contributes to the achievement of a correct diagnosis. Perimetry is performed in 
case of positive results of testing with ophthalmoscopy and/or tonometry. 
c The probability of visiting an ophthalmologist has been multiplied by the probability of being diagnosed. 
d The complementary probability to ‘success laser’ is the probability to switch to surgery. 
e The complementary probability to ‘success surgery’ is the probability to become blind.  
Strategy (1) = ‘tonometry all’; Strategy (2) = ‘tonometry high-risk group’ (the values shown are valid if 20% 
of OH and POAG and 5% of the rest of the patients report a positive family history of glaucoma); Strategy (3) 
= ‘tonometry no one’; Discovery = probability of discovering undiagnosed patients in part two of the model; 
Visitors = patients visiting the ophthalmologist regularly due to other ophthalmic condition than OH or 
POAG; Discharged = patients being discharged after the diagnostic process (part one of the model) is 
completed; Monotherapy = receiving 1 medication; Combination therapy = receiving more than 1 medication; 
Normal = has neither OH nor POAG 
 
 
 
Table 2: OH and POAG prevalence among initial ophthalmic patients12 
Age category OH POAG Normala 
40 - 49 years 16.7 % 0 % 83.3 % 
50 - 59 years 2.2 % 1 % 96.8 % 
60 - 69 years 5.3 % 1 % 93.7 % 
70 - 79 years 7.9 % 4 % 88.1 % 
80+ years 5.2 % 6.9 % 87.9 % 
All age-categories 6.7 % 2.4 % 90.9 % 
a normal = has neither OH nor POAG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 54
 
Table 3: Prices (2001) and frequency of the health care use 
Resource Patient type Frequency Unit price (€) 
Outpatient visita   23 
 OH patients with check-up only 1 / year  
 OH patients on monotherapy 1 / year  
 OH patients on combination therapy 1 / year  
 POAG patients on monotherapy 2 / year  
 POAG patients on combination therapy 2 / year  
 POAG patients post laserb 2 / year  
 POAG patients post surgeryc 2 / year  
 blind 0.5 / year  
Perimetry   77 
 OH patients on monotherapy 0.2 / year  
 OH patients on combination therapy 0.33 / year  
 POAG patients on monotherapy 1 / year  
 POAG patients on combination therapy 1 / year  
 POAG patients post laser 1 / year  
 POAG patients post surgery 1 / year  
Argon laser therapy POAG patients (by indication) 1 267 
Surgery POAG patients (by indication) 1 1 282 
Monotherapy patients on monotherapy daily 158 / year65 
Combination therapy patients on combination therapy daily 358 / year65 
Transportation  all patients per visit 3 
a 10 minutes consult: included are visus control, tonometry, ophthalmoscopy (the first consult costs 26 € if 
tonometry is included, and 24 € without tonometry)  
b plus 1 extra consult after the intervention 
c plus 10 extra consults after the intervention 
Results 
Table 4 gives the expected costs and outcomes per initial ophthalmic patient due to 
OH and POAG within a period of 20 years. Not surprisingly, both strategies ‘tono-
metry all’ and ‘tonometry high risk group’ cost more than ‘tonometry no one’ but 
also avert more blindness. The strategy ‘tonometry all’ is the most expensive one, 
with least blindness. For this strategy the incremental costs to prevent blindness in 
comparison with ‘tonometry no one’ are € 7 778 to prevent one person from becom-
ing blind and € 1 707 per year of vision saved. For strategy ‘tonometry high risk 
group’ the incremental costs to prevent blindness are higher. These outcomes do not 
include extra costs due to blindness, e.g. in connection with the usage of disability 
facilities. Since such costs are likely to exceed € 1 707 per year, inclusion of such 
costs makes the strategy ‘tonometry all’ cheapest and most effective. 
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The sensitivity analysis shows that in strategy ‘tonometry all’ the occurrence of 
blindness is always lowest and in strategy ‘tonometry no one’ always highest. The 
incremental costs to prevent blindness are always lower for the strategy ‘tonometry 
all’ than ‘tonometry high-risk group’. These results show the robustness of the 
conclusions. 
 
In a one-way sensitivity analysis the lower and upper bound values of all parame-
ters for which ranges are given were used. Alteration of glaucoma incidence among 
undiscovered OH patients has the largest impact on the results of the cost-
effectiveness analysis. The incremental costs per year of vision saved for strategy 
‘tonometry all’ are € 4 670, when glaucoma incidence among discharged OH 
patients is lowest and € 564 when it is highest. Alteration of blindness incidence 
among untreated glaucoma patients gives incremental costs per year of vision saved 
€ 3 900, when it is lowest, and € 1 240, when it is highest. A two-way sensitivity 
analysis, which uses the lower values of both above-mentioned parameters, gives 
the incremental costs € 12 250 per year of vision saved. Alteration of the health care 
costs, with all unit prices raised by 10% and 30%, has no substantial effect on the 
outcomes of the cost-effectiveness analysis (data not shown). Neither does an 
alteration of the cohort characteristics and of the sensitivity and specificity of the 
diagnostic tests (data not shown). 
 
Table 4: Results of the cost-effectiveness analysis of three different strategies for early detection and treatment 
of OH and POAG among initial ophthalmic patients 
a expected costs and effects per initial ophthalmic patient due to ocular hypertension or glaucoma within 20 
years (costs and years in blindness have been discounted by 4%)  
b the incremental cost-effectiveness ratio shows extra costs per effect in comparison with the strategy 
‘tonometry no one’ (ratio between the difference in costs and the difference in effects) 
Discussion 
This study evaluates the long-term consequences of three case-finding strategies, 
which differ with respect to the group of patients receiving tonometry. For this 
purpose a simulation model was used. Although a randomized clinical trial would 
be of interest, it is almost impossible to conduct. Beside the ethical objections such 
trial would inevitably give large expenses because of the low prevalence of glau-
coma and its slow progression to blindness. An advantage of modeling is the possi-
bility to simulate and compare several strategies. Another advantage is the possibil-
 Strategy 
‘tonometry all’ 
Strategy 
‘tonometry high-
risk group’ 
Strategy 
‘tonometry no 
one’ 
Costsa (€) 295 265 225 
Proportion of patients not becoming blinda 0.993 0.986 0.984 
Years of blindnessa 0.021 0.053 0.062 
Incremental cost-effectiveness ratiob 
(extra costs to prevent 1 person from becoming blind) 7 778 20 000 - 
Incremental cost-effectiveness ratiob 
(extra costs per year of vision saved) 1 707 4 444 - 
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ity to integrate current research results and examine the influence of alteration of 
different parameters. 
 
The figures incorporated in the model are based on information from different 
sources. This could give uncertainty about the exact value of the figures. A sensitiv-
ity analysis was performed to assess the impact of variation of the uncertain quanti-
ties in the model on the outcomes of the cost-effectiveness analysis. The conclu-
sions were robust to these uncertainties. 
 
To validate the simulation model strategy ‘tonometry all’, which represents more or 
less the current practice, was studied in more detail. The model shows that on 
average over a period of 20 years, each year 5.2% of glaucoma patients undergoes 
laser therapy and 2.7% surgery. A questionnaire, distributed among glaucoma 
patients in randomly chosen practices in the Netherlands, showed comparable 
results.39 Per year 4.8% of patients had laser therapy and 2% surgery. The model 
was further validated by comparing the incidence of glaucoma blindness to those 
reported in the literature. Two longitudinal studies were conducted in patients from 
a clinic.40,41 The incidence rate of blindness in these studies was 1.05% and 0.95% 
per year, respectively. The model shows an incidence rate of blindness 0.90% per 
year. 
 
The costs seem to be comparable to those reported in the literature. One study 
assessed the annual resource use and costs of patients in the Netherlands.42 The 
mean costs per glaucoma patient were € 469 (converted and using the retail price 
index). In the simulation model this is € 454. Another study calculated the direct 
treatment costs for newly diagnosed OH or POAG patients in Germany.43 The mean 
costs per OH/POAG patient for one year of treatment were about € 324 (converted 
and using the retail price index). The same authors calculated the costs for France 
and the United Kingdom.44 This was € 387 and € 560, respectively. Other published 
glaucoma cost studies show comparable estimates for yearly costs in Europe and 
Canada.45-47 In the U.S. the published yearly costs ranged from € 486 for early stage 
of the disease to € 1960 for patients with end-stage disease.48 Differences in unit 
costs, in medication prices, in the assignment of laser therapy and surgery, can 
explain some variations in the costs. However, raising the costs in our study did not 
affect its conclusions. 
 
The outcomes show that strategy ‘tonometry all’ is the most preferable in relation to 
blindness prevention. This strategy is most costly, but prevents most blindness. The 
incremental costs to prevent blindness when compared to ‘tonometry no one’ are 
small. For strategy ‘tonometry high risk group’ the incremental costs are higher. 
Even if the financing would be limited, it would be more preferable to perform 
tonometry in all patients, and not in high-risk group only, because strategy ‘tonome-
try all’ dominates strategy ‘tonometry high risk group’ in the extended sense.38 The 
costs due to blindness from glaucoma could not be retrieved. If such yearly costs 
exceed € 1 707, then performing tonometry in all patients becomes cost saving. This 
is likely the case because blindness is accompanied by the utilization of disability 
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facilities. In the Netherlands a common help in the household for disabled people 
(12 hours a week) has a yearly cost of € 5 300. The costs of blindness may vary per 
country depending on the care and support given. A study conducted in the United 
Kingdom, which took the societal perspective, estimated the costs of blindness for 
people with age related macular degeneration.49 The costs of blindness in this study 
were € 10 134 (€ 2 159- € 26 847) in the first year and € 9 883 (€ 2 080-€ 26 376) in 
the second and subsequent years (converted and using the retail price index). The 
same paper gives an overview of the estimates of the cost of blindness for UK, 
Scotland, Australia, USA and Switzerland. The yearly costs due to blindness in 
these countries probably exceed € 1 707. 
 
At first glance it is not obvious why strategy ‘tonometry all’ is the most cost-
effective because in general, approaching a high-risk group would give a higher 
yield of case-finding. However, in strategy ‘tonometry all’ not every detected OH 
patient is treated, as current guidelines advice only treatment in case of a presence 
of a risk factor. Those who are not treated at once are followed for the occurrence of 
glaucoma. Those who develop glaucoma are treated at an early stage; thereby 
blindness can still be prevented, and the costly treatment of those OH patients who 
never develop POAG can be avoided. When the proportion of high-risk patients 
receiving treatment was made similar to that in strategy ‘tonometry all’, the results 
became more alike, confirming that monitoring of OH patients without direct 
treatment contributes to a favorable cost-effectiveness ratio of strategy ‘tonometry 
all’. 
 
The impact of not using the ophthalmoscope to detect POAG has not been ad-
dressed. In daily practice ophthalmoscopy cannot be left out of the first ophthalmic 
examination. Its use is needed for the diagnosis of many diseases. Tonometry could 
be left out more easily since there is often no indication for it, except for the early 
detection of OH or POAG. The use of perimetry, costly and time consuming, is 
unlikely an option for case-finding. In the model patients undergo perimetry on 
indication, to confirm the diagnosis. 
 
A positive family history of glaucoma was appointed as an indication for being at 
risk of having glaucoma. It is an established risk factor and it is easy to assess in 
daily practice.11 It has been estimated that about 20% of the OH and POAG patients 
and 5% of others in the ophthalmic patients population report a positive family 
history of glaucoma.10,50 The simulations show that even if these proportions are 
much higher strategy ‘tonometry all’ remains the most cost-effective (data not 
shown). 
 
Note that normal tension glaucoma (NTG) is not included in this study. The role of 
IOP in its pathogenesis and the response to therapeutic lowering of IOP is different 
in comparison with high-tension glaucoma. Moreover, this disorder cannot be 
primarily detected by tonometry. As a consequence, inclusion of NTG in the study 
has no impact on the outcomes of the cost-effectiveness analysis, because the 
incremental costs and the incremental effects do not change. When NTG is in-
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cluded, the proportion of patients prevented from blindness due to glaucoma is 
slightly lower than calculated. 
 
The indirect costs have not been used in the presented analysis, because glaucoma 
effects mainly elderly and the consequences in terms of potential loss of production 
are limited.51 No cost-utility analysis has been performed. An estimate for the utility 
for blindness is 0.6.52 The estimated incremental costs per quality-adjusted life-year 
(QALY) for strategy ‘tonometry all’ are then approximately € 2 850. According to 
the guidelines in the Netherlands a 4% discount rate is used. Because of the current 
international recommendation of 3%, an extra analysis was performed.38,53 If using 
a 3% discount rate, the incremental costs per year of vision saved for ‘tonometry 
all’ are € 1 550. 
Conclusion 
The strategy ‘tonometry all’ is the most preferable strategy for blindness preven-
tion, with € 1 707 extra costs per year of vision saved when compared to strategy 
‘tonometry no one’. When costs associated with the use of disability facilities due 
to blindness exceed € 1 707 per patient per year, which is most likely, then strategy 
‘tonometry all’ becomes cost saving. We conclude that it is most cost-effective to 
routinely perform tonometry to all initial ophthalmic patients to prevent blindness 
due to glaucoma. 
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Abstract 
Objective: To assess the impact of two strategies for initiating therapy in ocular 
hypertension on intraocular pressure, drug use, and eventual blindness due to 
glaucoma. 
Design: A simulation model. 
Methods: Two strategies are modelled. In strategy (1) therapy is started with 
timolol, in strategy (2) with latanoprost. By Monte Carlo simulation the IOP lower-
ing effect of the specific drugs is applied to a hypothetical cohort of OH patients, 
characterized by an initial IOP distribution. Depending on the achieved IOP and 
occurrence of side effects, the prescribed therapy can be maintained or therapy 
switches occur, at most four times. The adjustment of therapy to reach the target 
pressure involves consecutively monotherapy, combination therapy, and laser. 
Switches to different types of monotherapy and combination therapy are included. 
Four drugs are used: latanoprost, timolol, brimonidine, and dorzolamide. After 15 
months of therapy adjustments a lifelong follow-up with possible conversion to 
glaucoma and to blindness is modeled (Markov model). Conversion rates depend on 
the achieved IOP. The parameters in the model are based on the literature, the 
cohort characteristics on the data of 1 000 patients. The analyses were performed 
for a cohort with a sampled and fixed initial IOP (25 and 30 mm Hg). 
Outcome measures: 1) drug distribution after 15 months 2) IOP after 15 months 3) 
blindness through glaucoma within a lifelong follow-up. 
Results: Treatment goal was achieved in both strategies in 90% by monotherapy. 
For a cohort with an initial IOP 30 mm Hg this was 60%. The originally prescribed 
medication was maintained in 66% in strategy (1) and in 77% in strategy (2). IOP 
decreased with approximately 34%, from 25.4 mm Hg (sampled mean) to 16.7 mm 
Hg in strategy (1) and to 16.5 mm Hg in strategy (2). The computed blindness per 
person within 18.7 years of life expectancy was 0.0923 years in strategy (1) and 
0.0870 years in strategy (2), which corresponds to approximately 1 month. The 
difference between strategies corresponds to 2 days spent in blindness per patient. 
Conclusion: Concerning the clinical effects of the two strategies, the differences 
are quite small. This is largely caused by the key concept of a target pressure, which 
underlies both strategies.  
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Introduction 
The introduction of new IOP lowering drugs in the last decades has contributed to a 
change of the drug prescription pattern for ocular hypertension (OH) and glau-
coma.1-3 An ophthalmologist can choose from a broad spectrum of hypotensive 
drugs. The IOP lowering effect, the ease of application, the occurrence of side-
effects, contraindications, and costs, are all important factors in drug choice. For 
many years, non-selective beta-blockers such as timolol have been the first choice 
in treatment. However, the use of beta-blockers is decreasing and hypotensive 
lipids, such as latanoprost, are becoming the most commonly prescribed drugs. One 
may question whether latanoprost should be the first choice in OH therapy instead 
of timolol. Latanoprost gives only a slightly better IOP lowering effect than ti-
molol.4 The cost price of latanoprost is, however, considerably higher than that of 
timolol. In the literature mostly a head-to-head comparison can be found between 
treatment with hypotensive lipids and treatment with timolol, based on the achieved 
IOP level. One study compared the effectiveness of treatment on the glaucoma 
progression as well, however, based on IOP reduction through timolol only and 
hypotensive lipids only.5 Such a comparison does not take into account essential 
aspects of patient management. In daily practice, therapies often get adjusted, even 
repeatedly. For each patient a target pressure is defined and a best fitting therapy is 
searched for, a therapy that achieves an optimal IOP reduction with minimal ad-
verse events. The goal of each treatment strategy is to reach the same target pres-
sure. Therefore, one may expect that such strategies will give similar clinical re-
sults. In this paper a simulation model is presented, which was used to quantita-
tively assess the clinical effects of initiating OH therapy with timolol or with la-
tanoprost. The details of therapy adjustments have been taken into account. The 
model is set up to compare the two strategies with respect to their impact on the 
IOP, drug use, and blindness due to glaucoma. Our analysis is focused on the 
difference in the clinical effects due to a different first therapy choice, followed by 
similar steps for therapy adjustments, for a cohort of OH patients as they enter an 
ophthalmic practice. 
Methods 
General design 
Two strategies for the initiation and adjustment of OH medication are modelled and 
compared. In strategy (1) therapy is started with timolol and in strategy (2) with 
latanoprost. By using a Monte Carlo simulation the IOP lowering effect of the 
specific drugs is applied to a hypothetical cohort of OH patients. This cohort is 
characterized by the initial IOP and age distributions. The adjustment of therapy in 
order to reach the target pressure is modelled as in the ophthalmic practice. Patients 
start therapy with a topical agent and return for evaluation. In case of adverse 
events, or unsatisfactory IOP decrease, therapy is adjusted and a new evaluation 
follows. Therapy switches are modelled at most four times. Therapies involve 
monotherapy, combination therapy and laser. Four drugs, representatives of four 
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major generic classes, are used: timolol (beta-blockers), latanoprost (hypotensive 
lipids), brimonidine (α2-adrenergic agonists), and dorzolamide (topical carbonic 
anhydrase inhibitors). The modelled IOP lowering effects are specific for each drug 
and for each drug combination. Effects correspond to timolol 0.5%, latanoprost 
0.005%, dorzolamide 2%, brimonidine 0.2%. Contraindication to timolol is taken 
into account. Once the therapy adjustments are completed, which covers at most 15 
months of therapy, per strategy the achieved new IOP distribution and the drug 
distribution within the cohort are determined. Subsequently by using a Markov 
model also a lifelong follow-up of the cohort and the disease progression over time 
are modelled. A conversion to glaucoma and to blindness can take place. Yearly 
conversion rates are dependent on the achieved IOP level. Per strategy the eventual 
years of blindness are determined. The time horizon of the model is based on the 
life expectancy of patients. The parameters used in the model are based on the 
literature. The IOP lowering effect of the specific drugs is based on a meta-analysis 
of randomized clinical trials.4 The estimates of other parameters are based on clini-
cal trials and long-term follow-up studies. Glaucoma specialists were consulted to 
decide which medication should be used in case of a therapy switch. The character-
istics of the simulated cohort are based on the data of 1 000 ophthalmic patients. 
The model 
The model is built by use of software package ‘Decision Analysis by TreeAge’ 
(Data), version 3.5. Input data and their sources are shown in Tables 1-3 and Fig-
ure 1. In addition, the survival probabilities are taken from data provided by the 
Dutch Central Bureau for Statistics (CBS).33 Conversion to blindness is based on an 
assumption that 1% of glaucoma patients per year become blind.34,35 The simulated 
cohort consists of initial OH patients (without glaucomatous changes of the optic 
nerve head or visual field loss) of at least 40 years old. Mean age is 64.5 years. 
Initial IOP within this population includes values from 22 to 35 mm Hg. Mean 
initial IOP value is 25.36 mm Hg. 
 
 
Figure 1: The IOP dependent yearly incidence of POAG in OH patients under treatment 21-32 
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Table 1: The initial IOP distribution of the simulated cohort6 
 
Two treatment strategies are set up as follows. In strategy ‘start with timolol’ 
patients start therapy with timolol unless contraindicated, in which case latanoprost 
is used. In strategy ‘start with latanoprost’ all patients start therapy with latanoprost. 
Both latanoprost and timolol are used in each strategy. A switch from latanoprost to 
timolol and vice versa is possible. In case of a therapy switch first latanoprost and 
timolol are used, brimonidine, and dorzolamide afterwards. Laser treatment follows 
only if there are no more treatment options through medication. Contraindication to 
timolol is taken into account at all places in the model where this drug is applied. 
The corresponding proportion of patients receives another medication. 
 
Table 2: IOP reduction through therapy used in the simulation model4,7-11 
Intervention IOP reduction (%) 
(mean ± SD) 
 
Timolol (0.5%) 26.5 ± 14  
Latanoprost (0.005%) 29.5 ± 13.4  
Dorzolamide (2%) 19.5 ± 13.5  
Brimonidine (0.2%) 21 ± 13.1  
Timolol + latanoprost (add on) 20.5 ± 13.9  
Timolol + dorzolamide (add on) 18 ± 12  
1 drug + 1 drug or laser (add on) 18 ± 12  
2 drugs + 1 drug or laser (add on) 10 ± 5  
3 drugs + laser (add on) 8 ± 4  
Laser 30 ± 12  
 
Table 3: Parameters used in the simulation model12-20 
Parameter Proportion 
(lower bound) 
Proportion 
(baseline) 
Proportion 
(upper bound) 
Contraindication timolol 0.1 0.2 0.3 
Side effect* timolol 0.05 0.1 0.3 
Side effect* latanoprost 0.01 0.03 0.1 
Side effect* dorzolamide  0.05 0.15 0.25 
Side effect* brimonidine  0.05 0.15 0.25 
* any side effects of medication that cause a therapy change 
 
Therapy adjustment is modelled within the structure of a decision tree. A simplified 
impression of the tree is given in Figure 2. Always three months after a prescription 
IOP (mm Hg) Proportion  
22 0.17  
23 0.16  
24 0.15  
25 0.13  
26 0.11  
27 0.08  
28 0.05  
29 0.04  
30 0.03  
31 0.02  
32 0.02  
33 0.02  
34 0.01  
35 0.01  
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of a medication an evaluation is modelled to take place. For each simulated patient 
a new IOP, achieved by the IOP lowering effect of the prescribed drug, and an 
occurrence of side effects are modelled probabilistically. A patient then either 
maintains the prescribed medication, or a therapy change follows with a subsequent 
new evaluation. Criteria for treatment adjustments are as follows. 1) If serious side 
effects occur, the drug is replaced with another one, regardless of the achieved IOP 
level. 2) In the absence of side effects the treatment assignment depends on the 
achieved IOP level as follows: a) If the achieved IOP is less than or equal to 21 mm 
Hg, medication is not changed. b) If the achieved IOP is higher than 21 mm Hg and 
the IOP reduction is more than 20% of the original IOP level another drug is added. 
c) If the achieved IOP is higher than 21 mm Hg and the IOP reduction is less than 
20% of the original IOP level, the currently used medication is substituted by 
another one. Laser treatment is assigned in the same way as a new drug, as an 
addition to the medication or as a replacement of it. Occurrence of side effects is 
independent of age or IOP. 
 
Figure 2: Visual representation of the therapy adjustments applied during the first 15 months of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* if target IOP reached or if all 4 steps have been evaluated, then continuation therapy  
† with respect to baseline IOP 
 
Subsequent lifelong follow-up is implemented as a Markov model. In a Markov 
model a set of independent states is defined and patients switch from one state to 
another at a regular interval (cycle) according to the transition probabilities. The 
following health states can be entered: ‘glaucoma’, ‘blindness’ and ‘death’. Age and 
sex dependent survival probabilities, an IOP dependent (per mm Hg) glaucoma 
incidence rate, and a yearly probability of becoming blind from glaucoma are 
included. In the model sex has been distributed equally. Transitions to the health 
states can take place always at the end of a 6 months cycle. The choice of the cycle 
length reflects the common time between consecutive outpatient visits. 
1st choice monotherapy Evaluation*
Target IOP reached
Target IOP not reached and
IOP reduction >= 20%†
Target IOP not reached and
IOP reduction < 20%†
or adverse events
step 1: change monotherapy
step 2: change monotherapy
step 3: change monotherapy
step 4: change to laser
step 1: add 2nd drug
step 2: add 3rd drug
step 3: substitute 3rd drug
step 4: addition of or change to laser
Continuation of therapy
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Analysis 
The analyses were performed for an initial IOP sampled from the distribution and 
additionally for the fixed values of the initial IOP: 25 and 30 mm Hg. The following 
outcomes were determined: 1) drug distribution after 15 months after initiation of 
therapy 2) IOP distribution and mean IOP within the cohort after 15 months after 
initiation of therapy 3) blindness through glaucoma within a lifetime follow-up. A 
sensitivity analysis was conducted for the outcomes of mean IOP and blindness. For 
this purpose the parameters for contraindication to timolol, the occurrence of side-
effects, and the IOP lowering effect of timolol and latanoprost were varied. Also 
analyses were conducted after an elimination of the IOP lowering effect of bri-
monidine, dorzolamide, and laser. In addition, for the outcome of blindness, a 
comparison was made with a simulated ‘no-treatment’ option. 
Results  
Drug use after 15 months after initiation of therapy 
The drug distribution within the cohort after the therapy adjustment is given in 
Table 4. In both strategies approximately 90% of the simulated patients use mono-
therapy. In a cohort of patients with an initial IOP of 30 mm Hg this is about 60%. 
The proportion of patients using initially prescribed medication is different per 
strategy. In strategy ‘start with timolol’ 53% of patients use monotherapy timolol 
and 32% monotherapy latanoprost. It must be noted that in this strategy it is mod-
eled that 20% of patients start therapy with latanoprost because of contraindication 
to timolol. Thus about 66% maintain the originally prescribed timolol. In strategy 
‘start with latanoprost’ 77.1% maintains the prescribed monotherapy latanoprost. 
The proportion of patients receiving combination therapy and/or laser treatment is 
similar for both strategies, even in the cohort of patients with IOP of 30 mm Hg.  
 
Table 4: Drug use 15 months after the initiation of OH therapy with timolol or with latanoprost, per strategy, 
for different values of the initial IOP 
 Strategy ‘start with timolol’ Strategy ‘start with latanoprost’ 
 IOP  
sample 
IOP 
25 mm Hg
IOP 
30 mm Hg
IOP 
sample 
IOP 
25 mm Hg 
IOP 
30 mm Hg 
Monotherapy       
     timolol 53.0 % 55.8 % 28.8 % 8.0 % 10.2 % 7.6 % 
     latanoprost 32.0 % 35.8 % 23.8 % 77.1 % 81.8 % 47.5 % 
     brimonidine or dorzolamide 5.8 % 7.1 % 7.8 % 5.8 % 6.9 % 7.9 % 
Combination of 2 drugs       
     timolol+latanoprost  2.0 % 0.0 % 9.3 % 3.4 % 0.0 % 16.1 % 
     timolol+dorzolamide 1.5 % 0.0 % 7.3 % - - - 
     dorzolamide+ brimonidine 0.4 % 0.0 % 1.7 % 0.4 % 0.0 % 1.6 % 
     timolol+(dorzolamide or brimonidine) 0.0 % 0.0 % 0.1 % 1.2 % 0.0 % 5.1 % 
     latanoprost+(dorzolamide or  
     brimonidine) 3.0 % 0.0 % 12.8 % 1.4 % 0.0 % 6.6 % 
Combination of 3 drugs       
     various combinations of timolol,  
     latanoprost, dorzolamide, brimonidine 1.2 % 0.0 % 4.3 % 1.2 % 0.0 % 4.1 % 
Laser treatment 1.9 % 1.2 % 5.8 % 2.1 % 1.2 % 5.7 % 
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IOP after 15 months of treatment 
In Figure 3, for the cohort with sampled IOP, an IOP distribution after therapy 
adjustment is given for both strategies. The patterns of distribution seem superim-
posible. Nevertheless, values of 19 mm Hg and higher are more frequent in strategy 
‘start with timolol’, 30% against 27%, and complementary values of 18 mm Hg and 
lower are more frequent in strategy ‘start with latanoprost’, 73% against 70%. The 
mean IOP values are shown in Table 5. The initial IOP decreased with approxi-
mately 34% from 25.4 mm Hg (sampled mean) to 16.7 (±0.017) mm Hg in strategy 
‘start with timolol’ and to 16.5 (±0.013) mm Hg in strategy ‘start with latanoprost’. 
In a cohort of patients with an initial IOP of 30 mm Hg the IOP decrease in both 
strategies was about 69%, to 17.5 mm Hg. 
 
 
 
Figure 3: IOP distribution after 15 months of treatment per strategy, for a cohort with a sampled initial IOP 
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Years of blindness due to glaucoma 
In Table 5 for each strategy the expected years of blindness due to glaucoma per 
patient are given. The computed time with blindness per patient is 0.0923 (33.7 
days) years in strategy ‘start with timolol’ and 0.0870 (31.8 days) years in strategy 
‘start with latanoprost’. This corresponds to approximately 1 month of blindness per 
patient, over a period of 18.7 years, which is the computed mean life expectancy in 
the cohort. The difference between the strategies is 2 days of blindness, a difference 
of about 6%. For reference, a ‘no treatment’ simulation (0% IOP reduction through 
medication and laser) shows 0.492 expected years of blindness per patient, which 
corresponds to approximately 6 months of blindness. 
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Sensitivity analysis 
In a one-way sensitivity analysis the parameters for contraindication to timolol and 
occurrence of side-effects have been varied within the given ranges, as given in 
Table 3. This had however, minimal impact on the mean IOP or blindness (data not 
shown). In Table 5 other results of the sensitivity analysis are shown. The IOP 
lowering effects of timolol and latanoprost were varied within the range of a 95% 
confidence interval around the given value, in which the lower and upper bounds 
for both drugs represent about 2% more or less IOP reduction.4 A two-way sensitiv-
ity analysis with 2% less IOP reduction through timolol and 2% more IOP reduction 
through latanoprost shows a difference in blindness, which corresponds to 5 days 
per patient, in favor of strategy ‘start with latanoprost’. 
 
 
Table 5: Treatment effects of two different strategies for initiating OH therapy, (1) ‘start with timolol’ or (2) 
‘start with latanoprost’, for different values of the initial IOP 
 Initial IOP = sample Initial IOP = 25 mm Hg Initial IOP = 30 mm Hg 
 Strategy (1)
(timolol) 
Strategy (2)
(latanoprost)
Strategy (1)
(timolol) 
Strategy (2)
(latanoprost)
Strategy (1) 
(timolol) 
Strategy (2) 
(latanoprost) 
  
 IOP change through medication after 15 months of therapy 
(mm Hg) 
Basic analysis 16.66 
± 0.017* 
16.52 
± 0.013 
16.88 
± 0.016 
16.74 
± 0.014 
17.49 
± 0.008 
17.49 
± 0.011 
Sensitivity analysis        
0% IOP reduction through 
laser 
16.73 
± 0.005 
16.57 
± 0.016 
16.92 
± 0.020 
16.77 
± 0.018 
17.67 
± 0.014 
17.67 
± 0.010 
0% IOP reduction through 
laser, dorzolamide en 
brimonidine 
17.02 
± 0.014 
16.84 
± 0.024 
17.17 
± 0.019 
17.00 
± 0.019 
18.35 
± 0.014 
18.27 
± 0.018 
2% less IOP reduction through 
timolol and 2% more IOP 
reduction through latanoprost 
16.66 
± 0.019 
16.22 
± 0.022 
16.85 
± 0.011 
16.42 
± 0.011 
17.36 
± 0.008 
17.29 
± 0.001 
  
 Blindness through glaucoma† 
(years of blindness) 
Basic analysis 0.0923 
± 0.0012 
0.0870 
± 0.0010 
0.0977 
± 0.0011 
0.0924 
± 0.0011 
0.1175 
± 0.0008 
0.1173 
± 0.0012 
Sensitivity analysis       
0% IOP reduction through all 
medication and laser (no 
treatment) 
0.4924 
± 0.0031 
0.4924 
± 0.0031 
0.4555 
± 0.0038 
0.4555 
± 0.0038 
0.7741 
± 0.0059 
0.7741 
± 0.0059 
0% IOP reduction through 
laser 
0.0969 
± 0.0013 
0.0923 
± 0.0022 
0.1003 
± 0.0007 
0.0953 
± 0.0013 
0.1301 
± 0.0013 
0.1299 
± 0.0009 
0% IOP reduction through 
laser, dorzolamide en 
brimonidine 
0.1092 
± 0.0021 
0.1040 
± 0.0020 
0.1107 
± 0.0004 
0.1047 
± 0.0002 
0.1546 
± 0.0023 
0.1535 
± 0.0024 
2% less IOP reduction through 
timolol and 2% more IOP 
reduction through latanoprost 
0.0934 
± 0.0015 
0.0807 
± 0.0017 
0.0982 
± 0.0007 
0.0854 
± 0.0007 
0.1160 
± 0.0012 
0.1130 
± 0.0012 
* standard deviation for the average, computed from 5 Monte Carlo simulations of size 20 000 each  
† mean expected time spent in blindness per person within 18.7 years of life expectancy 
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Discussion 
The difference in impact on IOP or blindness of the two analyzed treatment strate-
gies was minimal. The model shows that from the clinical point of view it does not 
matter by which medication therapy should be initiated. Many OH patients can 
reach their target pressure with any first choice medication, whether timolol or 
latanoprost. For them, glaucoma development and blindness will be acceptably 
small; only slight differences will apply. For patients with a high initial IOP a 
similar situation arises, since treatment adjustments are also aimed to reach the 
target pressure. If the target pressure is achieved, clinical effects of the different 
strategies will again be very similar. Otherwise more therapy adjustments will occur 
to achieve a best possible treatment and the effect of the initial choice largely 
cancels out. 
 
The choice for a simulation model requires some attention. The alternative of a 
clinical trial would inevitably be associated with large expenses, particularly due to 
a long follow-up. One of the advantages of modeling is the ability to predict events 
in the long-term. A simulation of a lifetime follow-up of a cohort of patients can be 
performed. Hence, in a short time period long-term results can be assessed. Another 
advantage is that different scenarios can be constructed by changing the influential 
factors. A model also allows a real life simulation, such as no treatment strategy, 
without placing patients at risk. Moreover, by applying a Monte Carlo simulation, 
which is run 100 000 times, a reliable estimate of the clinical result of a strategy 
given the underlying variation is obtained (see the calculated standard deviations 
given in Table 5). 
 
The parameters used in the model are taken from different sources and do not 
represent an exact value. We have attempted to use the best available data from the 
literature. A range of values was tested to determine the robustness of the qualita-
tive conclusions drawn from the analysis. The outcomes of the sensitivity analysis 
did not alter the conclusions of the study. 
 
To validate the model a process known as “debugging” the tree was applied, to 
avoid modeling or programming errors.36 Also, a comparison was made with clini-
cal outcomes of OH treatment, as known from the literature. The design of the 
Ocular Hypertension Treatment Study (OHTS) corresponds well with the modelled 
therapy approach.37 In the OHTS study therapy was initiated with a topical agent 
and medication was subsequently changed and/or added, if required, until the 
treatment goals were met or the participant was receiving the maximum tolerated 
topical medical therapy. In the OHTS study the baseline pressure was 24.9±2.7 mm 
Hg. In the modelled cohort this was 25.4±3.0 mm Hg. The model showed approxi-
mately 34% IOP reduction through medication. In the OHTS study the IOP reduc-
tion in the medication group was smaller, namely 22.5±9.9%. There are several 
explanations for this. Firstly, the treatment goals of the studies differ in the target 
pressure criterion, this being 24 mm Hg in the OHTS study and 21 mm Hg in the 
model. Secondly, in the OHTS study the average IOP across follow-up visits is 
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given, whereas the model outcomes show a mean IOP value after the therapy 
adjustments are completed. Thirdly, when treatment of the OHTS study participants 
started, the treatment choice was limited, as some of the hypotensive drugs, were 
not available yet. 
 
In the model no difference is made between beginning and advanced glaucoma. The 
yearly estimate for blindness applies to all glaucoma patients. This might be slightly 
overestimated. The IOP reduction through various medications is taken from a meta 
analysis of randomized clinical trials.4 The age and IOP distributions within the 
cohort of initial OH patients were selected from the charts of 1 000 initial patients, 
consecutively visiting a regional non-referral ophthalmic practice in Maastricht 
(Medisch Centrum Maastricht Annadal - MCMA), starting from January 1999. The 
global characteristics of these distributions have been verified to be consistent with 
the literature.38-40 
 
In summary, we believe that our model approaches the clinical practice closely, 
uses the optimal current data, and produces results that are reliable. 
Conclusions 
Concerning the clinical effects of the two strategies of initiating OH therapy with 
latanoprost or with timolol, the differences are quite small. This is largely caused by 
the key concept of a target pressure, which underlies both treatment strategies. As it 
turns out, this target pressure can be achieved fairly easily by both strategies for 
many patients. 
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Abstract 
Objective: To determine the long term cost-effectiveness of treatment of ocular 
hypertension (OH) with latanoprost compared to timolol. 
Design: A cost-effectiveness simulation model. 
Methods: Two strategies are modelled. In strategy (1) therapy is started with 
timolol, in strategy (2) with latanoprost. By Monte Carlo simulation the IOP lower-
ing effect of the specific drugs is applied to a hypothetical cohort of OH patients, 
characterized by an initial IOP distribution. Depending on the achieved IOP and 
occurrence of side effects the prescribed therapy can be maintained or changed, at 
most four times. In a short term decision analytic model the adjustment of therapy 
to reach the target pressure involves consecutively monotherapy, combination 
therapy, and laser. Switches to different types of monotherapy and combination 
therapy are included. Four drugs are used: latanoprost, timolol, brimonidine, and 
dorzolamide. After 15 months of therapy adjustments a lifelong follow-up with 
possible conversion to glaucoma and to blindness is modeled (Markov model). 
Conversion rates depend on the achieved IOP. The direct medical costs are as-
signed. The parameters in the model are based on the literature and on the data of  
1 000 patients. The analyses were performed with a sampled initial IOP and with 
fixed values of 25 and 30 mm Hg. 
Outcome measures: 1) mean IOP after 15 months of therapy 2) mean expected 
costs after 15 months of therapy 3) blindness through glaucoma within a lifetime 
follow-up 4) mean expected lifetime costs. 
Results: The IOP decreased from 25.4 mm Hg (sampled mean) to 16.7 mm Hg in 
strategy (1) and to 16.5 mm Hg in strategy (2). In strategy (1) the mean expected 
time spent in blindness per patient within 18.7 years of life expectancy is 0.0334 
years and the lifetime costs are € 3 514 and in strategy (2) 0.0318 years and € 4 397, 
respectively (4% discount used). The computed extra costs per year of vision saved 
for strategy (2) in comparison with strategy (1) amount to € 537 000. For patients 
with an initial IOP of 30 mm Hg this is € 7 068 000. These cost-effectiveness ratios 
are increasing with age, from € 222 632 for the 40-years old to € 1 057 025 for the 
70-years old. 
Conclusion: It is computed, with the current cost price of latanoprost, that for 
saving one year of vision about € 537 000 extra is needed when therapy in OH 
patients is initiated with this drug compared to initiation with timolol. 
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Introduction 
The approach towards treatment of ocular hypertension (OH) and primary open-
angle glaucoma (POAG) has changed in recent years. This is partly due to the 
introduction of new hypotensive agents, but also because of publication of the 
results of several randomized trials, which show the benefit of treatment in OH 
patients or in patients with early glaucoma.1-3 Recent research in various European 
countries indicates an increased number of treated patients, more aggressive treat-
ment, and a change in therapy prescription pattern.4-7 The rising costs in glaucoma 
treatment can only be justified if associated with an adequate reduction in visual 
disability. The aim of therapy is to reduce increased intraocular pressure (IOP), a 
major risk factor in the development of glaucoma, and so prevent future visual 
deterioration and thus blindness. 
 
Nowadays, hypotensive lipids are becoming the most commonly prescribed class of 
glaucoma drugs.6 Of these, latanoprost reduces IOP most and is currently often used 
as the drug of first choice instead of the beta-blocker timolol. However, its hypoten-
sive effect is only slightly better than that of timolol,8 whereas the costs are much 
higher. Considering the costs and effects of these agents one may question whether 
it is cost-effective to change the initiation of therapy with timolol to latanoprost in 
OH patients. In the clinical trials an evaluation of the effectiveness of a specific 
glaucoma drug is based on its IOP lowering effect as monotherapy. However, it is 
important to realize, that patient management in the clinical practice often involves 
therapy switches and even combined therapies, in order to reach a target pressure 
for each patient. 
 
In the present study, two strategies of initiating therapy in patients with ocular 
hypertension, starting with latanoprost or starting with timolol are modelled and 
evaluated for effects and costs. The two strategies are modelled as in the ophthalmic 
practice, including therapy adjustments, to reach a target pressure. Considering that 
this is the aim of both treatment strategies, one may expect small difference in the 
achieved IOP reduction. Which strategy is more cost-effective, may thus depend on 
whether the achieved difference in IOP will translate, in the long-term, in a reduc-
tion of glaucoma development and blindness that will outweigh the cost expenditure 
for OH medication. This study is performed from the societal perspective. 
Methods 
General design 
Two strategies for the initiation and adjustment of OH medication are modelled and 
compared. In a previous study we have already assessed the short and long-term 
clinical effects of these strategies. In the present study we have assigned direct 
medical costs of treatment and calculated the incremental costs and effects of the 
two strategies, according to the standards of a cost-effectiveness analysis.9,10 We 
use the same model as described earlier (paper submitted for publication). 
Chapter 6 
 78
In strategy (1) therapy is started with timolol and in strategy (2) with latanoprost. 
By using a Monte Carlo simulation the IOP lowering effect of the specific drugs is 
applied to a hypothetical cohort of OH patients. This cohort is characterized by the 
initial IOP and age distributions. First the adjustment of therapy is modelled. Pa-
tients start therapy with a topical agent and return for evaluation. In case of adverse 
events, or unsatisfactory IOP decrease, therapy is adjusted and a new evaluation 
follows. Therapy switches are modelled at most four times. Therapies involve 
different types of monotherapy, combination therapy, and laser. Four drugs are 
used, representing four major generic classes: timolol (beta-blockers), latanoprost 
(hypotensive lipids), brimonidine (α2-adrenergic agonists), and dorzolamide (topi-
cal carbonic anhydrase inhibitors). The modelled IOP lowering effects are specific 
for each drug and for each drug combination. Effects correspond to timolol 0.5%, 
latanoprost 0.005%, dorzolamide 2%, brimonidine 0.2%. Contraindication to 
timolol is taken into account. Once the therapy adjustments are completed, which 
covers at most 15 months of therapy, the achieved new IOP distribution and the 
drug distribution within the cohort are determined per strategy. Subsequently by 
using a Markov model a lifelong follow-up and the disease progression over time 
are modelled. A conversion to glaucoma and to blindness can take place. Yearly 
conversion is dependent on the IOP achieved after 15 months of treatment. Per 
strategy the eventual years of blindness are determined. The time horizon of the 
model is based on the life expectancy of patients. The IOP reductions through 
therapy, side-effects and contraindication of medication, glaucoma incidence and 
blindness development are based on the literature. The age and initial IOP distribu-
tions are based on the data of 1 000 ophthalmic patients. Glaucoma specialists were 
consulted to decide which medication should be used in case of a therapy switch. 
 
The hypothetical cohort consists of initial OH patients (without glaucomatous 
changes of the optic nerve head or visual field loss) of at least 40 years old. Mean 
age is 64.5 years. Initial IOP within this population includes values from 22 to 35 
mm Hg. Mean initial IOP value is 25.4 mm Hg. 
The therapy adjustments (decision model) 
Therapy adjustment is modelled within the structure of a decision tree. The output 
of this decision model forms the input for the Markov model, which covers the 
lifelong follow-up. A simplified impression of the models is given in Figure 1. Two 
treatment strategies are set up as follows. In strategy ‘start with timolol’ patients 
start therapy with timolol unless contraindicated, in which case latanoprost is used. 
In strategy ‘start with latanoprost’ all patients start therapy with latanoprost. Both 
latanoprost and timolol are used in each strategy. A switch from latanoprost to 
timolol and vice versa is possible. In case of a therapy switch first latanoprost and 
timolol are used, followed by brimonidine, and dorzolamide. Laser treatment 
follows only if there are no more treatment options through medication. Contraindi-
cation to timolol is taken into account at all places in the model where this drug is 
applied. The corresponding proportion of patients with contraindication receives 
different medication. 
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Every three months after a prescription of a medication an evaluation is modelled to 
take place. For each simulated patient a new IOP, achieved by the IOP lowering 
effect of the prescribed drug, and an occurrence of side effects are modelled prob-
abilistically. A patient then either maintains the prescribed medication, or a therapy 
change follows with a subsequent new evaluation. Criteria for treatment adjust-
ments are as follows. 1) If serious side effects occur, the drug is replaced with 
another one, regardless of the achieved IOP level. 2) In the absence of side effects 
the treatment assignment depends on the achieved IOP level as follows: a) If the 
achieved IOP is less than or equal to 21 mm Hg, medication is not changed. b) If 
the achieved IOP is higher than 21 mm Hg and the IOP reduction is more than 20% 
of the original IOP level another drug is added. c) If the achieved IOP is higher than 
21 mm Hg and the IOP reduction is less than 20% of the original IOP level, the 
currently used medication is substituted by another one. Laser treatment is assigned 
in the same way as a new drug, as an addition to the medication or as a replacement 
of it. Occurrence of side effects is independent of age or IOP. 
The lifelong follow-up (Markov model) 
The lifelong follow-up is implemented within the structure of a Markov model. In a 
Markov model a set of independent states is defined and patients switch from one 
state to another at a regular interval (cycle) according to the transition probabilities. 
For all possible outcomes of medication assignment health states are defined, which 
can be entered. This takes place after the therapy adjustments are finished. At the 
end of the first 15 months period each simulated patient has his specific IOP 
achieved through therapy and a specific medication prescription. The initial health 
states are entered according to this specific medication. Subsequently during the 
follow-up the following health states can be entered: ‘death’, ‘glaucoma’, and 
‘blindness’. Age and sex dependent survival probabilities, an IOP dependent (per 
mm Hg) glaucoma incidence rate, and a yearly probability of becoming blind from 
glaucoma are included. In the model sex has been distributed equally. Transitions to 
the health states can take place always at the end of a 6 months cycle. The cycle 
length reflects the common time between consecutive outpatient visits. 
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Cost assignment 
The health care costs are assigned as once-only costs and state dependent costs. The 
once-only costs are the costs of outpatient visits, medication and laser therapy, 
related to the first 15 months of treatment. For each simulated patient these costs are 
added up. The state dependent costs are the costs related to OH and POAG treat-
ment during life time follow-up in the Markov model. These costs are assigned to 
the health states and reflect the treatment requirements related to 6 months of 
treatment of a particular state. For each OH patient the costs involve the costs of 
outpatient visits and the specific costs of the prescribed medication. Once a conver-
sion to POAG takes place, then POAG costs are assigned. These are the same for all 
patients and represent the average costs of a glaucoma patient in the Netherlands, 
including the costs of outpatient visits, perimetry, laser trabeculoplasty, surgery, 
and medication. 
Model input 
Input data and their sources are shown in Tables 1-4 and Figure 2. The age and IOP 
distribution for the population have been determined from the charts of 1 000 initial 
patients, consecutively visiting a general ophthalmic practice in Maastricht 
(Medisch Centrum Maastricht Annadal - MCMA), starting from January 1999. The 
prices of medical drugs represent the prices in the Netherlands (incl. VAT). The 
unit prices related to outpatient visits and laser trabeculoplasty are as determined at 
the University Hospital Maastricht. This was done according to the micro costing 
method.9 The average treatment costs of a POAG patient were taken from a previ-
ous study of the authors (Eye advance online publication, 24 November 2006; 
doi:10.1038/sj.eye.6702637). The frequency of the health care use is modeled in 
accordance with the specialists’ opinion and the recommendations of the American 
Academy of Ophthalmology.11 The survival probabilities are taken from data 
provided by the Dutch Central Bureau for Statistics (CBS).12 Conversion to blind-
ness is based on an assumption that 1% of glaucoma patients per year become 
blind.13,14 
 
Figure 2: The IOP dependent yearly incidence of POAG in OH patients under treatment1,2,45-54 
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Table 1: Initial IOP of the simulated cohort30 
 
 
 
 
 
Table 2: IOP reduction by therapy used in the simulation model8,31-35 
Intervention IOP reduction (%) 
(mean ± SD) 
 
Timolol (0.5%) 26.5 ± 14  
Latanoprost (0.005%) 29.5 ± 13.4  
Dorzolamide (2%) 19.5 ± 13.5  
Brimonidine (0.2%) 21 ± 13.1  
Timolol + latanoprost (add on) 20.5 ± 13.9  
Timolol + dorzolamide (add on) 18 ± 12  
1 drug + 1 drug or laser (add on) 18 ± 12  
2 drugs + 1 drug or laser (add on) 10 ± 5  
3 drugs + laser (add on) 8 ± 4  
Laser 30 ± 12  
 
 
 
 
 
Table 3: Parameters used in the simulation model23,36-43 
Parameter Proportion 
(lower bound) 
Proportion 
(baseline) 
Proportion 
(upper bound) 
Contraindication timolol 0.1 0.2 0.3 
Side effect* timolol 0.05 0.1 0.3 
Side effect* latanoprost 0.01 0.03 0.1 
Side effect* dorzolamide  0.05 0.15 0.25 
Side effect* brimonidine  0.05 0.15 0.25 
* any side effects of medication that cause a therapy change 
 
 
 
 
 
IOP (mm Hg) Proportion  
22 0.17  
23 0.16  
24 0.15  
25 0.13  
26 0.11  
27 0.08  
28 0.05  
29 0.04  
30 0.03  
31 0.02  
32 0.02  
33 0.02  
34 0.01  
35 0.01  
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Table 4: The cost prices of medication and the health care unit prices (2001)44 
 Cost price  
Timolol (0.5%) 5.10 € / month  
Latanoprost (0.005%) 18.67 € / month  
Dorzolamide (2%) 12.86 € / month  
Brimonidine (0.2%) 14.32 € / month  
Timolol + latanoprost (add on) 22.79 € / month  
Timolol + dorzolamide (add on) 17.59 € / month  
Outpatient visit (15 min) 27.57 €  
Outpatient visit (10 min) 23.85 €  
Perimetry 80.93 €  
Laser 279.42 €  
Transportation (per visit) 2.9 €  
Glaucoma therapy* 450 € / year  
* average costs of a glaucoma patient including outpatient visits, medication, perimetry, laser, and surgery 
 
Analysis 
A Monte Carlo simulation was used to sample from the age, sex, and initial IOP 
distributions within the cohort, and the distributions of IOP reduction through 
specific medication and/or laser. The analyses were performed for an initial IOP 
sampled from the distribution and additionally for the fixed values of the initial 
IOP: 25 and 30 mm Hg. The following outcomes were determined per strategy: 
1) mean IOP within the cohort after 15 months after initiation of therapy 2) mean 
expected costs after 15 months of therapy 3) blindness through glaucoma within the 
lifetime follow-up 4) mean expected lifetime costs. The analysis was performed 
with a discount rate of 4%, for both costs and effects, and without a discount. A 
subgroup and sensitivity analyses were performed for the fixed values of the initial 
IOP: 25 and 30 mm Hg, with a 4% discount rate. In a subgroup analysis the ex-
pected costs and years of blindness per strategy were determined apart for patients 
aged 40, 50, 60 and 70 years. In a one-way sensitivity analysis the contraindication 
for timolol, the side effects of medication, the cost of glaucoma therapy and the cost 
price of latanoprost have been varied. A two-way sensitivity analysis was carried 
out for the IOP lowering effect of timolol and latanoprost. 
Results 
Outcomes after 15 months of treatment: IOP and expected costs 
The initial IOP decreased with approximately 34% from 25.4 mm Hg (sampled 
mean) to 16.7 (±0.017) mm Hg in strategy ‘start with timolol’ and to 16.5 (±0.013) 
mm Hg in strategy ‘start with latanoprost’. For patients with a fixed initial IOP of 
30 mm Hg the IOP decrease was about 69%, in both strategies to about 17.5 mm 
Hg. The calculated costs per patient 15 months after initiation of therapy were € 367 
(±0.66) in strategy ‘start with timolol’ and € 469 (±0.39) in strategy ‘start with 
latanoprost’. For patients with an initial IOP of 30 mm Hg these costs were € 441 
(±0.33) and € 496 (±0.53), respectively. 
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Outcomes within a lifetime follow-up: blindness due to glaucoma and expected 
costs 
In Table 5 for each strategy years of blindness due to glaucoma and expected 
lifetime costs per patient are given. The computed time with blindness per patient is 
0.0923 (33.7 days) years in strategy ‘start with timolol’ and 0.0870 (31.8 days) 
years in strategy ‘start with latanoprost’ (without discount). This corresponds to 
approximately 1 month of blindness per patient, over a period of 18.7 years, which 
is the computed mean life expectancy in the cohort. The difference between the 
strategies is 2 days of blindness, a difference of about 6%, in favor of strategy ‘start 
with latanoprost’. For reference, a ‘no treatment’ simulation (0% IOP reduction 
through medication and laser) showed 0.492 expected years of blindness per pa-
tient, which corresponds to approximately 6 months. 
 
Table 5: Results of the cost-effectiveness analysis of two different strategies for initiating treatment of ocular 
hypertension (analyses with sampled and fixed values of the initial IOP) 
The values represent the expected lifetime costs and effects for a treated OH patient (an average computed 
from 5 Monte Carlo simulations of size 20 000 each); * mean expected time spent in blindness per person 
within 18.7 years of life expectancy; ** the incremental cost-effectiveness ratio shows extra costs per year of 
vision saved when starting therapy with latanoprost compared to starting with timolol; *** standard deviation 
for the average, computed from 5 Monte Carlo simulations of size 20 000 each 
 
The calculated expected lifetime costs include the costs of the first 15 months of 
therapy as well. The lifetime costs are lower for strategy ‘start with timolol’ than for 
strategy ‘start with latanoprost’, namely € 5 456 against € 6 794 (€ 3 514 against 
 Strategy 
‘start with timolol’ 
Strategy 
‘start with latanoprost’ 
4% discount (costs and effects)   
Initial IOP sampled   
   costs (€) 3 514 ± 13.670*** 4 397 ± 15.014 
   years of blindness* 0.0334 ± 0.0004 0.0318 ± 0.0004 
   incremental C/E** - 536 852 
Initial IOP = 25 mm Hg   
   costs (€) 3 396 ± 4.056 4 304 ± 4.378 
   years of blindness 0.0361 ± 0.0004 0.0344 ± 0.0003 
   incremental C/E - 547 276 
Initial IOP = 30 mm Hg   
   costs (€) 4 215 ± 6.394 4 583 ± 10.708 
   years of blindness 0.04301 ± 0.0002 0.04296 ± 0.0004 
   incremental C/E - 7 068 037 
   
0% discount (costs and effects)   
Initial IOP sampled   
   costs (€) 5 456 ± 23.929 6 794 ± 27.790 
   years of blindness 0.0923 ± 0.0012 0.0870 ± 0.0010 
   incremental C/E - 253 011 
Initial IOP = 25 mm Hg   
   costs (€) 5 269 ± 18.760 6 628 ± 17.188 
   years of blindness 0.0977 ± 0.0011 0.0924 ± 0.0011 
   incremental C/E - 254 150 
Initial IOP = 30 mm Hg   
   costs (€) 6 556 ± 18.142 7 099 ± 13.767 
   years of blindness 0.1175 ± 0.0008 0.1173 ± 0.0012 
   incremental C/E - 2 009 703 
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€ 4 397 discounted). For patients with an initial IOP of 30 mm Hg the difference in 
costs is smaller, namely € 6 556 against € 7 099 (€ 4 215 against € 4 583 dis-
counted). The outcomes of the subgroup analysis are given in Table 6. The differ-
ence in costs and effects between the strategies becomes smaller with an increasing 
age. 
Sensitivity analyses 
The outcomes of the sensitivity analyses are partially shown in Table 6. The varia-
tion of the transition probabilities of contraindication for timolol and side effects of 
medication within the given ranges (see Table 3) had hardly any influence on the 
outcomes (data not shown). Lowering the costs of glaucoma therapy from 
€ 450/year to € 350/year, or increasing it to € 600/year, gives only a slight decrease 
or increase of the lifetime costs in both strategies, about 0.8-1.5%. Analyses with a 
reduced price of latanoprost, from € 18.7/month to € 10/month and € 6/month, show 
a marked reduction and vanishing of the cost difference between the strategies. 
With a reduced price of latanoprost, for patients with an initial IOP of 30 mm Hg, in 
strategy ‘start with latanoprost’ the lifetime costs are lower than in strategy ‘start 
with timolol’. The IOP lowering effects of timolol and latanoprost were varied 
within the range of a 95% confidence interval around the given value, in which the 
lower and upper bounds for both drugs represent about 2% more or less IOP reduc-
tion.8 A two-way sensitivity analysis with 2% more IOP reduction through latano-
prost and 2% less IOP reduction through timolol shows better blindness prevention 
for a cohort with an initial IOP 25 mm Hg in strategy ‘start with latanoprost’, and 
with an initial IOP 30 mm Hg in both strategies. 
Cost-effectiveness 
According to the simulations strategy ‘start with timolol’ is cheaper than strategy 
‘start with latanoprost’ but yields more years of blindness. In tables 5 and 6 the 
incremental cost-effectiveness ratios are given. These are calculated as a ratio 
between the difference in costs and the difference in effects between the two strate-
gies and represent extra costs per year of vision saved when initiating therapy with 
latanoprost compared to initiating with timolol. If therapy is initiated with latano-
prost the computed extra costs per year of vision saved in comparison to initiation 
with timolol amount to € 537 000. An analysis with a fixed initial IOP of 30 mm Hg 
shows a reduced difference in costs and almost no difference in blindness between 
the two strategies. For such patients extra costs per year of vision saved become 
much higher and amount to € 7 068 000. 
 
The subgroup analyses per 10-years age categories show that extra costs per year of 
vision saved when initiating therapy with latanoprost compared to timolol, are 
increasing with age, from € 222 632 for the 40-years old to € 1 057 025 for the 
70-years old. When the price of latanoprost is reduced, the cost-effectiveness ratio 
becomes smaller and drops even to € 44 095, if the price is € 6/month. For patients 
with a fixed IOP of 30 mm Hg strategy ‘start with latanoprost’ then becomes cost 
saving. 
 
Chapter 6 
 86
Table 6: Results of the subgroup and sensitivity analyses 
 Initial IOP = 25 mm Hg Initial IOP = 30 mm Hg 
4% discount (costs and effects) Strategy 
‘start with 
timolol’ 
Strategy 
‘start with 
latanoprost’ 
Strategy 
‘start with 
timolol’ 
Strategy 
‘start with  
latanoprost’ 
A. Subgroup analysis 
     
Age: 40 years     
   costs (€) 5 414 ± 1.364*** 6 797 ± 2.222 6 712 ± 7.813 7 261 ± 7.620 
   years of blindness* 0.1218 ± 0.0006 0.1156 ± 0.0007 0.1453 ± 0.0004 0.1447 ± 0.0003 
   incremental C/E** - 222 632 - 912 363 
     
Age: 50 years     
   costs (€) 4 716 ± 2.157 5 942 ± 4.177 5 866 ± 9.311 6 356 ± 14.177 
   years of blindness 0.0749 ± 0.0005 0.0712 ± 0.0004 0.0892 ± 0.0002 0.0893 ± 0.0004 
   incremental C/E - 334 809 - - 8 786 078**** 
     
Age: 60 years     
   costs (€) 3 848 ± 5.543 4 874 ± 4.547 4 804 ± 9.425 5 219 ± 5.903 
   years of blindness 0.0380 ± 0.0002 0.0361 ± 0.0003 0.0454 ± 0.0003 0.0452 ± 0.0003 
   incremental C/E - 552 352 - 3 320 995 
     
Age: 70 years     
   costs (€) 2 885 ± 4.400 3 668 ± 1.688 3 607 ± 5.437 3 929 ± 1.861 
   years of blindness 0.0145 ± 0.0001 0.0138 ± 0.0001 0.0175 ± 0.0001 0.0175 ± 0.0000 
   incremental C/E - 1 057 025 - 18 182 688 
     
B. Sensitivity analysis 
     
Cost glaucoma therapy 
350 € / year 
    
   costs (€) 3 347 ± 8.779 4 253 ± 7.471 4165 ± 5.290 4530 ± 9.849 
   years of blindness 0.0361 ± 0.0002 0.0343 ± 0.0003 0.0428 ± 0.0006 0.0427 ± 0.0005 
   incremental C/E - 506 138 - 3 453 151 
     
Cost glaucoma therapy  
600 € / year 
    
   costs (€) 3 446 ± 10.226 4 340 ± 8.563 4303 ± 2.503 4671 ± 8.284 
   years of blindness 0.0353 ± 0.0003 0.0336 ± 0.0002 0.0429 ± 0.0002 0.0429 ± 0.0002 
   incremental C/E - 528 171 - 5 226 625 
     
Cost latanoprost 0.005%  
10 € / month 
    
   costs (€) 2 964 ± 9.027 3 326 ± 11.926 3 666 ± 6.358 3 756 ± 6.301 
   years of blindness 0.0360 ± 0.0003 0.0339 ± 0.0004 0.0425 ± 0.0001 0.0425 ± 0.0001 
   incremental C/E - 174 394 - -2 271 388**** 
     
Cost latanoprost 0.005%  
6 € / month 
    
   costs (€) 2 751 ± 5.945 2 828 ± 5.806 3 368 ± 3.385 3 307 ± 4.260 
   years of blindness 0.0359 ± 0.0003 0.0341 ± 0.0003 0.0428 ± 0.0003 0.0426 ± 0.0002 
   incremental C/E - 44 095 - - 324 031***** 
     
IOP reduction: timolol 2% less 
and latanoprost 2% more 
    
   costs (€) 3 467 ± 7.314 4 344 ± 13.292 4 324 ± 12.942 4 626 ± 9.037 
   years of blindness 0.0360 ± 0.0003 0.0313 ± 0.0002 0.0423 ± 0.0003 0.0414 ± 0.0002 
   incremental C/E  186 068 - 317 103 
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The values represent the expected lifetime costs and effects for a treated OH patient (an average computed 
from 5 Monte Carlo simulations of size 20 000 each).  
* mean expected time spent in blindness per person within 18.7 years of life expectancy  
** incremental cost-effectiveness ratio shows extra costs per year of vision saved when starting therapy with 
latanoprost compared to starting with timolol  
*** standard deviation for the average, computed from 5 Monte Carlo simulations of size 20 000 each  
**** higher costs, less effect in strategy ‘start with latanoprost’  
***** lower costs, more effect in strategy ‘start with latanoprost’ 
Discussion 
The results of the modeling study show that initiating therapy in OH patients with 
latanoprost brings along extremely high incremental costs, € 537 000 extra for 
saving one year of vision when compared to initiating therapy with timolol. If 
treatment with latanoprost only and timolol only would be compared, there would 
undoubtedly be a significant difference in treatment effects between those two 
drugs. However, a comparison of clinically based strategies, where different first 
therapy choice is followed by similar steps for therapy adjustments to achieve a 
target pressure, shows minimal difference in the achieved IOP and blindness 
through glaucoma between the two analyzed strategies. The computed cost differ-
ence on the other hand, is large. As the IOP reduction is similar in both strategies, 
with a consequence that only slight differences occur in glaucoma development and 
blindness, the corresponding glaucoma costs will be comparable in both strategies 
as well. The different OH therapy costs are thus responsible for the main cost 
difference, as confirmed by the results of the sensitivity analysis. 
 
Many OH patients can reach their target pressure with timolol as well as with 
latanoprost. Patients whose target pressure cannot be easily reached and controlled 
with monotherapy need more therapy adjustments including combination therapy or 
laser treatment. This is however, the case in both strategies and the costs for these 
patients will thus be comparable. Long-term use of monotherapy with latanoprost is 
a largest contributor to the higher cost expenditure in the strategy ‘start with latano-
prost’. When starting therapy with latanoprost, the less expensive, but fairly enough 
sufficient, alternative for patients who can easily reach a target pressure with both 
drugs is not considered. This is the underlying reason why the strategy ‘start with 
latanoprost’ is not preferable from the cost-effectiveness point of view, in compari-
son to the strategy ‘start with timolol’. The modelled simulations show that even for 
young OH patients, who have a longest life expectancy and thus most time to 
develop glaucoma and blindness, it is not cost-effective to initiate therapy with 
latanoprost. 
 
A simulation model was used to analyze the two treatment strategies. Since we 
were able to incorporate data of recent, adequately performed, randomized clinical 
trials we believe that the results of our modelled strategies validly represent the 
current practice. Moreover, the long-term effects of the strategies could be assessed 
in a short time period. Another advantage of modeling is the evaluation of different 
modifications of the strategies as well, by changing the key parameters in the 
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model. By applying a Monte Carlo simulation, which is run 100 000 times, a reli-
able estimate of the clinical result of a strategy given the underlying variation is 
obtained (see the calculated standard deviations given in Tables 5 and 6). Extensive 
sensitivity analyses were performed to establish the impact of a variation of the 
uncertain values in the model on the outcomes and the study conclusions. It showed 
that these conclusions were robust. Only a reduction of the cost of latanoprost leads 
to a favorable cost-effectiveness ratio for the strategy ‘start with latanoprost’. 
 
To avoid modeling or programming errors a process known as ‘debugging’ the tree 
was applied.15 Further, a comparison was made with the facts known from the 
literature. The model showed approximately 34% IOP reduction through medica-
tion and laser. In the Ocular Hypertension Treatment Study (OHTS), the design of 
which corresponds well with the modelled therapy approach, this was 22.5±9.9%. 
However, the target pressure criterion differs, this being 24 mm Hg in the OHTS 
study and 21 mm Hg in the model. Laser treatment was not applied in the OHTS 
study participants. Further in the OHTS study the average IOP across follow-up 
visits is given, whereas the model gives a mean IOP value after the therapy adjust-
ments. Lastly, the treatment choice was limited, when the OHTS study participants 
started their therapy. The yearly estimate for blindness might be slightly overesti-
mated in the model, because no difference is made between beginning and ad-
vanced glaucoma. The age and IOP distributions of the population are verified to be 
consistent with the literature.16,17,18 IOP values above 35 mm Hg were not addressed 
in the model, because such values are very likely to be already associated with 
glaucoma. The IOP reduction through specific medication is based on the best 
current data, namely on a meta-analysis of randomized controlled trials.8 
 
There have been some studies published, addressing the cost-effectiveness of 
various treatments with glaucoma drugs.19,20 However, no sensible comparison of 
our results with these studies can be made, because they include treatment of glau-
coma and ocular hypertension. The drug persistency in glaucoma treatment is 
different than in ocular hypertension. Moreover, these studies use IOP as an out-
come measure. In one epidemiological study, by using a questionnaire in 1513 
patients, a drug use in ocular hypertension in Belgium was established.21 This was 
done in 1992 and 96% of patients were using a topical beta-blocker, many other 
types of ocular hypotensive drugs were not available yet. A median value of five 
years showed that in 77% the drug therapy involved only one drug. In the model 
about 66% of patients maintain the originally prescribed timolol after 15 months of 
treatment. Another cross-sectional study in France, with retrospective data collec-
tion for the preceding 5 years, found that 82.6% of patients with ocular hyperten-
sion were using monotherapy medication.22 The majority of patients were using a 
beta-blocker. In the model approximately 90% of patients uses monotherapy medi-
cation. In the same study the annual treatment costs for OH patients were € 275, 
€ 376 and € 476 for patients with 0, 1, and 2 treatment changes. In the model the 
mean costs calculated for 12 months of treatment were approximately € 295 for 
strategy ‘start with timolol’ and € 375 for strategy ‘start with latanoprost’. The 
proportion of patients with no treatment change in the model was 68% in strategy 
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‘start with timolol’ and 77.1% in strategy ‘ start with latanoprost’. The average 
treatment costs of a POAG patient used in the model match with the outcomes of 
other glaucoma cost studies.23-29 The costs due to blindness in connection with the 
usage of disability facilities in the Netherlands could not be retrieved. Even if these 
costs would be added, this should not influence the outcome of the study, because 
there is almost no difference in blindness between the two analyzed strategies. In 
the model a 4% discount is rate used, while internationally a 3% rate is recom-
mended.9 This was done due to the guidelines in the Netherlands, however, if 3% is 
used no substantial changes occur (data not shown). No utility analysis has been 
performed. The main purpose of the study was to assess and compare the impact of 
two different approaches of starting medication in OH patients. In summary we 
believe that the results of our modeling study can be regarded as reliable, since our 
model approaches clinical practice closely, we used recent estimates of treatment 
efficacy, and the intermediate results are in general consistent with existing reports. 
Conclusions 
Initiating therapy in OH patients with latanoprost brings along extremely high 
incremental costs to prevent blindness when compared to initiating therapy with 
timolol. Given the current cost price of latanoprost, saving one year of vision would 
incur € 537 000 of expenditures. These incremental costs are even higher for pa-
tients with a high initial IOP and are increasing with age. 
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In this thesis the clinical effects and cost-effectiveness of early detection and treat-
ment of ocular hypertension (OH) and primary open-angle glaucoma (POAG) are 
studied. The main questions investigated are closely linked to clinical practice and 
are the following. (1) Should patients with OH or early POAG be treated? (2) Is 
early detection and treatment of OH and POAG by an ophthalmologist beneficial 
for the prevention of blindness? (3) Which case-finding strategy applied in the 
ophthalmic practice is the most cost-effective? (4) What is the clinical impact of 
initiation of OH treatment with a new type of glaucoma medication in comparison 
with the medication used so far? (5) Is such a strategy of initiating OH treatment 
with a new type of medication cost-effective in comparison with the existing strat-
egy? 
 
In studying cost-effectiveness it is difficult to take all the costs and effects properly 
into account because glaucoma is an irreversible slowly progressive disease and a 
long-term follow-up is required. In view of the absence of long-term empirical data, 
meta-analysis and simulation models have been used to acquire insight in these 
issues. Two outcome measures are of most interest for clinical practice: (1) the 
conversion from OH (i.e. an increased intraocular pressure (IOP) in the absence of 
structural and functional damage) to POAG, and (2) the eventual progression of 
POAG to blindness. Costs are associated with medical diagnosis and treatment on 
one side, and with blindness related impairment on the other side. 
 
 
 
 
Figure 1. Framework for the illustration of the glaucoma related research in this thesis 
 
In Figure 1 a framework is presented which illustrates the research in the various 
chapters of this thesis, and clarifies their interrelationships. Currently, treatment of 
glaucoma is aimed at its main risk factor: an increased intraocular pressure. The 
IOP plays a key role in its diagnosis and detection on the one hand, whereas lower-
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ing of the IOP is the only effective treatment at present on the other hand. Future 
developments, for instance in the area of neuroprotection, may lead to different 
treatment strategies. 
 
The effectiveness of OH treatment 
For many decades now, lowering of the IOP is the cornerstone of glaucoma treat-
ment. Even though it is widely recognized that an elevated IOP contributes to 
glaucomatous optic neuropathy, there is great inter-individual variation in the 
susceptibility of the optic nerve to IOP-related damage.1 The Baltimore Eye Survey, 
which is a population-based study, indicates that only one-tenth or less of patients 
with an elevated IOP have glaucomatous field loss.2 Whether the IOP should be 
lowered in patients with ocular hypertension has repeatedly been a subject of dis-
cussion among ophthalmologists. The study described in Chapter 2 in this thesis has 
started in 2001. At that time, only the results of a few randomized trials were avail-
able which included OH patients. These studies were small in size and gave no 
conclusive scientific evidence on the effect of OH treatment. A major step forward 
has been the publication of the results of the Ocular Hypertension Treatment Study 
in 2002.3 There it was shown that topical ocular hypotensive medication is effective 
in delaying or preventing the onset of POAG in individuals with an elevated IOP.3 
In 2005 the results of another major study, the European Glaucoma Prevention 
Study, became available.4 This study has also shown a protective effect of OH 
treatment although it failed to confirm this at a statistically significant level. 
 
In this thesis, a quantification of the effect of IOP reduction in OH patients on the 
occurrence of glaucoma is given in Chapter 2, in which the results of a meta-
analysis of OH trials are described. An advantage of this meta-analytical approach 
is that by combining data of several comparable studies, the results of a large 
number of patients can be included, and relatively small effects can be detected or 
excluded with confidence.5 The pooled relative risk, expressing the protective effect 
of IOP lowering therapy on the conversion of OH to POAG, is estimated as 0.61 
(95% confidence interval 0.45 to 0.83). Additional regression analysis shows that a 
larger medically achieved decrease in IOP is associated with a larger reduction of 
the risk of conversion from OH to glaucoma. By using a meta-regression model it is 
estimated that the relative risk of conversion to glaucoma decreases by 14% with 
each mm Hg of IOP reduction. 
 
The OH trials included in the meta-analysis all have a limited follow-up, with a 
maximum of 6 years. Therefore, these trials cannot directly be used to assess the 
impact of OH treatment on the prevention of glaucoma blindness. Clearly, time 
aspects need to be addressed when studying such long-term effects of treatment. 
Ocular hypertension is rare under the age of 40 and glaucoma mostly affects elderly 
people. Also, it is a slowly progressive disease, so many patients will not live long 
enough to reach the end stage and become blind. To properly take such time related 
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issues into account, it is necessary to consider age and corresponding mortality 
rates, which change over time and are gender dependent. 
 
In the absence of empirical data, the simulation model presented in Chapters 5 and 
6 allows one to investigate time related issues as mentioned above. In this model the 
simulated cohort is based on the demographic characteristics of initial patients 
visiting an ophthalmic practice. Two strategies are modelled for initiating OH 
treatment with two different types of medication; the outcome measure is glaucoma 
blindness. For both treatment strategies, the expected time of blindness per patient 
is found to correspond with approximately 1 month over a period of 18.7 years, 
which is the mean life expectancy in the cohort. In a simulation where patients were 
only treated after conversion to glaucoma, the expected time of blindness per 
patient corresponds to approximately 6 months. These results indicate that OH 
treatment is beneficial for the prevention of glaucoma blindness in a population 
where age distribution resembles that of patients visiting an ophthalmic practice. 
 
Currently, therapy for OH patients is mostly recommended when IOP is above 29 
mm Hg or when IOP exceeds 21 mm Hg in the presence of other risk factors for 
POAG.6 However, most patients enrolled in the OH trials included in the meta-
analysis had an initial IOP between 24 mm Hg and 32 mm Hg and only some had 
additional risk factors. This implies that future research may be conducted on this 
topic. Also, for elder patients it may well turn out that the adverse effects of treat-
ment counterbalance the expected gain in blindness prevention, so that age depend-
ent treatment strategies may be developed. 
Cost-effectiveness of early detection and treatment of OH and POAG 
A cost-effectiveness analysis is a form of economic evaluation where both the costs 
and the consequences of health programmes or treatments are examined.7 As a 
consequence of changes in knowledge, facilities, equipment and costs over time, the 
existing programmes may once in a while need to be re-evaluated, and new strate-
gies may be developed and compared with existing ones. 
 
Within health care an identification and a comparison of strategies for detection 
and/or treatment are of interest. In the past, medical treatment options in glaucoma 
management were limited. The economic evaluations were generally focused on the 
efficacy of different diagnostic tools for OH and POAG detection8 and on the 
evaluation of different screening strategies in the general population.9,10 The feasi-
bility and efficacy of a screening program is still an issue of ongoing debate and 
screening in the general population is not recommended at present.11 However, in 
the last decades many new developments in the field of glaucoma took place, 
including new technologies that permit earlier detection of glaucomatous structural 
and functional damage, and new hypotensive treatments, which allow for safer and 
more effective IOP reduction. In a number of well-conducted clinical trials the 
effectiveness of treatment has been investigated and target pressures are now play-
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ing a key part in modern therapy strategies. However, new technologies and strate-
gies also bring along higher costs and the economic evaluation has shifted towards 
the cost-effectiveness of treatment. 
 
Treatment nowadays has become more complex through the availability of a broad 
spectrum of hypotensive agents, and different combinations of these. These drugs 
differ in their IOP lowering effects, topical and systemic side-effects, and costs. 
New diagnostic technologies allow for a better distinction of various stages of 
glaucoma progression. This is favourable for early detection of OH and POAG and 
also for a set up of more sophisticated treatment strategies. Also utility scores may 
be measured and defined for different degrees of vision loss. By adjusting life 
expectancy with the utility scores, quality-adjusted life years (QALYs) can be 
calculated, which has become an increasingly popular outcome measure for re-
source allocation.12 However, utility scores do carry an element of subjectivity and 
are not easy to assess consistently, and the impact of the loss of vision of one eye is 
largely influenced by the remaining functionality of the other eye. In the recently 
published cost-utility analysis of the Ocular Hypertension Treatment Study,13 the 
impact of OH treatment is evaluated in terms of QALYs for a simulated cohort of 
patients with an initial IOP of ≥ 24 mm Hg. In the present thesis we have instead 
considered years of blindness as the main outcome measure. 
 
In Chapters 4 and 6, two cost-effectiveness evaluations are presented: an evaluation 
of different case-finding strategies to detect OH and POAG by an ophthalmologist, 
and an evaluation of different strategies for the initiation of OH treatment. Both 
models include treatment of OH and POAG, and the main outcome measure is 
blindness due to glaucoma. In the model in which the case-finding strategies are 
simulated, an interaction of both detection and treatment is taken into account. In 
the other presented model, initiation of OH treatment followed by therapy adjust-
ments based on clinical practice is simulated. This differs from other evaluations of 
the new generation of hypotensive drugs which mostly involve a head-to-head 
comparison of two different agents.14,15 
 
As already mentioned above, screening for glaucoma in the general population is 
not recommended at present. In 1968 Wilson and Jungner proposed criteria for new 
screening programs, adopted by the World Health Organization, which should be 
fulfilled before their introduction in practice.16 The most important criteria are the 
following. (1) The condition sought should be an important health problem for the 
individual and community. (2) The natural history of the disease should be ade-
quately understood. (3) There should be an early pre-clinical phase during which 
the individuals with the disease can be identified. (4) There should be appropriate, 
acceptable, and reasonably accurate screening tests. (5) There should be an agreed 
policy on whom to treat as patients. (6) There should be an accepted and effective 
treatment which should be more effective in preventing morbidity when initiated 
early. (7) The costs of case finding should be economically balanced in relation to 
possible expenditure on medical care as a whole. Glaucoma meets many of these 
criteria, but not completely. Criteria 1, 3 and 4 are fulfilled, even though the screen-
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ing tests are amenable to further improvement. Criteria 2, 5, 6 and 7 are partially 
fulfilled and subject of ongoing discussion. 
 
The outcomes of Chapter 4 express the consequences of ophthalmic care versus no 
care, dependent on the yield of case-finding in the ophthalmic practice. The most 
preferable strategy for glaucoma-related blindness prevention is to perform tonome-
try to all initial ophthalmic patients. When costs associated with the use of disability 
facilities due to blindness exceed € 1 707 per patient per year, which is most likely, 
this strategy not only is effective in blindness prevention but in fact becomes cost 
saving. This outcome is consistent with the findings of the performed systematic 
review in Chapter 2 and the case-referent study described in Chapter 3, which 
indicate that early treatment of OH and POAG is effective in preventing blindness 
due to glaucoma. 
 
In addition, it can be noted that there are several other factors than IOP (e.g., blood 
supply to the optic nerve, substances toxic to the optic nerve or retina, axonal or 
ganglion cell metabolism, and the lamina cribrosa extracellular matrix), that may 
play a role in the progressive optic neuropathy of POAG.1 If one were able to 
identify subgroups of patients who are more susceptible to high intraocular pressure 
than others, treatment strategies could be applied which take this into account. This 
would positively influence the cost-effectiveness of the chosen strategies through an 
improved balancing of monitoring and treatment. 
 
The outcomes of the model presented in Chapters 5 and 6 show that it is not prefer-
able to start OH therapy with latanoprost, which gives more IOP reduction but is 
also more expensive, instead of timolol. Due to the concept of a target pressure, 
which underlies both strategies, the eventual difference in the clinical effects of the 
two strategies is small. When therapy is started with latanoprost, the extra costs 
needed for saving one year of vision in comparison with starting with timolol are 
very high, namely € 537 000. A different future cost price of latanoprost may affect 
this outcome. 
Conclusions and recommendations 
The research conducted in this thesis shows that: (1) topical hypotensive therapy 
reduces the risk of conversion to POAG in OH and a progression of visual field loss 
in early glaucoma, (2) early detection and treatment of OH and POAG is likely to 
be beneficial in the prevention of blindness, (3) it is most cost-effective to routinely 
perform tonometry to all initial ophthalmic patients to prevent blindness due to 
glaucoma, (4) the differences in the clinical effects of the two strategies of initiating 
OH therapy, with latanoprost or with timolol, are quite small, (5) given the current 
cost price of latanoprost, initiating therapy in OH patients with this agent brings 
along extremely high incremental costs to prevent blindness when compared to 
initiating therapy with timolol. 
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Further research topics that are suggested by the outcomes of the performed studies 
are the following. (1) To establish more accurate guidelines for when to start OH 
treatment based on the IOP level, the presence of other risk factors and life expec-
tancy, related to the expected gain in the prevention of blindness. (2) To identify 
subgroups of patients to which treatment strategies can be tailored. This may in-
volve aspects such as the initial IOP level, risk factors, prognostic factors, severity 
of the disease at the moment of diagnosis, and life expectancy. (3) To identify the 
most cost-effective strategies for such different subgroups of patients. 
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Summary 
In this thesis, both the clinical effectiveness and the cost-effectiveness of detection 
and treatment of patients with ocular hypertension (OH) and primary open-angle 
glaucoma (POAG) are investigated. POAG, further referred to as glaucoma, is a 
progressive chronic eye disease which can ultimately lead to blindness. It has a 
considerable public health impact, being the second leading cause of world-wide 
blindness (cataract being the first). The etiology of glaucoma is unknown. It mostly 
affects elderly people. Individuals with ocular hypertension are at risk to develop 
glaucoma. In these individuals the intraocular pressure (IOP) is increased above 
values which clinicians consider safe. A chronic increased intraocular pressure as 
such causes no symptoms and can only be detected if tonometry is performed. The 
probability of developing glaucoma increases with higher IOP values. Other known 
risk factors are race, age, and family history of glaucoma.  
 
Glaucoma is characterized by damage of the optic nerve. This leads to impairment 
of visual function. The disease manifests itself mostly by defects in the peripheral 
visual field first. Patients may not notice this for a long period. At later stages 
glaucoma may progress to tunnel vision and irreversible blindness. Although glau-
coma cannot be cured, its progression can be reduced by treatment. As the rate of 
progression of the disease is higher at high IOP levels, therapy is directed towards 
lowering the IOP. In clinical trials it was shown that IOP lowering therapy reduces 
the risk of conversion to glaucoma in OH patients (Ocular Hypertension Treatment 
Study) and that it has a protective effect on a progression in POAG patients (Early 
Manifest Glaucoma Trial, Advanced Glaucoma Intervention Study). However, 
individuals vary in their ability to sustain increased IOP. Not all OH patients de-
velop glaucoma. On the other hand, some glaucoma patients show progression 
despite a lowering of the intraocular pressure. IOP is therefore not the only factor 
that plays a role in the pathogenesis and progression of glaucoma. Other factors 
involved in the glaucomatous optic neuropathy are not well researched yet. IOP is 
at present the only factor manageable by treatment. Therapy involves hypotensive 
medication, laser treatment and surgery. The main therapeutic goal is to preserve 
visual function and to prevent the end stage of the disease. To achieve this goal it is 
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important that patients are detected in time. There are several tests available for 
diagnosing glaucoma. The IOP can be measured, the head of the optic nerve can be 
visualised, and the status of the visual field can be examined. Mostly a combination 
of tests is necessary to confirm the diagnosis. 
 
For an effective management of glaucoma an understanding of the treatment effects 
is crucial. As glaucoma is a chronic disease the long-term effects should be taken 
into account. This is difficult as clinical trials mostly have a limited follow-up. 
However, recently several large clinical trials have become available in which 
patients were followed for a long period. Another major issue in the management of 
this chronic disease are the costs of treatment. In the last decades, these have sub-
stantially risen as a consequence of the introduction of new types of topical hy-
potensive drugs. These drugs are expensive but they have expanded the existing 
treatment options. There is a broad spectrum of drugs available now. There are 
several options for the initiation of therapy in case of contraindication to more 
classical drugs. When no or too little IOP reduction is achieved with the prescribed 
drug or if side-effects occur, other drugs are available. Finally, there are several 
different drugs which can be added to the prescribed medication when larger IOP 
reduction than the one achieved already is required. To define ideal treatment 
strategies for OH and POAG patients is a complex task requiring many factors to be 
taken into account. 
 
One of the key questions is whether patients with ocular hypertension should be 
treated or not. After all, these patients do not have glaucoma yet, at least not detect-
able by current diagnostic techniques. Apart from costs, treatment is accompanied 
by discomfort and possibly by side-effects of medication. In favor of treatment are 
the results presented in this thesis which show that a therapeutic lowering of IOP in 
these patients reduces the risk of glaucoma. To assess the effects of treatment a 
long-term follow-up and a comparison of the conversion rates of patients with and 
without treatment is required. Although in the past many OH patients did receive 
treatment, there was little evidence on its efficacy until recently. In Chapter 2 all 
available scientific evidence on treatment effects in ocular hypertension is pre-
sented, based on a systematic literature review. The results of nine randomized 
clinical trials, in which OH patients with and without IOP lowering treatment were 
followed, are combined in a meta-analysis. This analysis shows that IOP lowering 
therapy in OH patients reduces the risk of conversion to glaucoma. The calculated 
pooled relative risk is 0.61 (95% confidence interval 0.45-0.83). In addition, it is 
shown that this relative risk decreases by 14% with each mm Hg of IOP reduction. 
At this moment, there is insufficient knowledge to identify OH patients who are at 
greater risk to develop glaucoma if untreated. Therapy for OH patients is generally 
recommended in case of high IOP values or if other risk factors are present. How-
ever, many patients included in the OH trials have IOP values below the recom-
mended cut-off point when treatment is indicated and only some have additional 
risk factors. This implies that future research might be directed towards this topic. 
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The assumption behind strategies aimed at detecting and treating patients with 
ocular hypertension and early glaucoma is that this prevents blindness. In Chapter 3 
a case-referent study is presented in which the effect of early detection of OH and 
POAG patients on the occurrence of glaucoma blindness is investigated. An expo-
sure to screening tests for early detection of OH and POAG performed by an oph-
thalmologist, not based on the disease symptoms, is assessed for a group of cases 
and a group of referents. Cases are blind glaucoma patients. Referents represent the 
general population regarding the frequency of such testing. The underlying argu-
mentation in this study is as follows. If patients undergo testing for OH and POAG 
detection while not having any disease symptoms, the disease is diagnosed and 
treated at an early stage. If treatment of OH and early glaucoma is effective in 
blindness prevention then one can assume that patients diagnosed at this stage will 
not progress to blindness. Conversely, the reason that blind patients did progress to 
blindness is that they were not detected (and treated) in time. The outcomes of the 
study confirm this supposition. Blind glaucoma patients underwent fewer screening 
examinations by which OH or POAG can be detected than the referents. The calcu-
lated relative risk is 0.57 (90% confidence interval 0.31-1.05). This study shows 
that detecting patients with OH and early glaucoma in the ophthalmic practice is 
effective in preventing glaucoma blindness. 
 
At present there is no recommendation for a population screening program for 
glaucoma. The best alternative to detect patients early is case-finding among pa-
tients visiting an ophthalmologist. There are several alternatives as to how to ad-
dress this issue. An interesting question concerning case-finding in the ophthalmic 
practice is whether IOP should be routinely measured in all initial patients, or only 
in selected groups of patients having risk factors for glaucoma. Ophthalmoscopy, by 
which the head of the optic nerve can be viewed, is mostly included in an ophthal-
mic examination. Tonometry on the other hand, has no other purpose than to detect 
an increased IOP. This test can easily be performed without much burden for a 
patient. A consequence of testing with tonometry is that more patients, mainly OH 
patients, will be detected and treated. Apart from the clinical effect this has an 
effect on costs. In Chapter 4 the long-term costs and effects of three different case-
finding strategies are studied and evaluated by use of a decision model. Tonometry 
is routinely performed to: (1) all initial patients, (2) high-risk patients only, or (3) 
no one. These strategies are compared according to the methods of a cost-
effectiveness analysis. It is concluded that it is most cost-effective to perform 
tonometry to all initial ophthalmic patients to prevent blindness due to glaucoma. 
Extra costs per year of vision saved are € 1 707 compared to strategy where tono-
metry is performed to no one. It is likely that costs a patient spends per year due to 
blindness, e.g. associated with the use of disability facilities, already exceed this 
amount. 
 
The main costs in glaucoma treatment are the medication costs. The introduction of 
new IOP lowering drugs in the last decades has contributed to a change of the drug 
prescription pattern, accompanied by a considerable rise of treatment costs. For 
many years, non-selective beta-blockers such as timolol have been the first choice 
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in treatment. Nowadays, hypotensive lipids such as latanoprost are commonly used 
as first-line therapy. Latanoprost gives only a slightly better IOP lowering effect 
than timolol. Its cost price on the other hand, is much higher. The costs and clinical 
effects of the drugs should both be considered when choosing the type of medica-
tion. Especially in case of a drug used for the initiation of therapy, as many patients 
will use it for a long period. When sufficient IOP reduction is achieved in absence 
of side-effects, a patient will continue on this medication. Only if necessary, a drug 
substitution or a drug addition will follow. For patients with ocular hypertension it 
is not necessary to lower the IOP to the same extent as for glaucoma patients. 
Therefore, given the higher price of hypotensive lipids, one could question if initia-
tion of therapy in OH patients with these agents is justified. 
 
In Chapter 5 an analysis is presented in which the long-term clinical effects of 
initiating OH therapy with timolol and with latanoprost are studied and compared. 
In Chapter 6 a cost-effectiveness analysis of these two strategies is given. A simula-
tion model is used for this purpose. In this model not only therapy initiation but also 
the adjustments of therapy are taken into account. The difference in the achieved 
IOP reduction between the two strategies is small. As conversion to glaucoma 
depends on IOP, the difference in glaucoma blindness between the strategies is 
small too. On average, this is about 1 month per person in both strategies, with a 
mean difference between the two strategies of 2 days spent in blindness per patient. 
On the other hand, the difference in costs spent on therapy between the two strate-
gies is large. This is why initiating treatment in OH patients with latanoprost brings 
along extremely high incremental costs to prevent blindness when compared to 
initiating therapy with timolol. Given the current cost price of latanoprost, extra 
costs per year of vision saved are € 537 000.  
 
Chapter 7 concludes this thesis with a general discussion and an outlook on future 
research. Recommendations for future research are to develop more accurate guide-
lines for when to start OH treatment and to identify subgroups of patients to which 
treatment strategies can be tailored.  
 
 
 
 
 
 
 
 
 105 
Samenvatting 
In dit proefschrift worden de klinische effecten en de kosteneffectiviteit bestudeerd 
van strategieën voor de detectie en de behandeling van patiënten met oculaire 
hypertensie (ocular hypertension, OH) en primair open-kamerhoek glaucoom 
(primary open-angle glaucoma, POAG). Laatstgenoemde aandoening, kortweg 
aangeduid met glaucoom, is een progressieve chronische oogziekte die uiteindelijk 
kan leiden tot blindheid. Het belang voor de volksgezondheid is groot, aangezien 
het, na cataract, wereldwijd de tweede oorzaak van blindheid betreft. De etiologie 
van glaucoom is onbekend. De ziekte treft hoofdzakelijk ouderen. Patiënten met 
oculaire hypertensie lopen een verhoogd risico op glaucoom. Bij deze patiënten 
neemt de intraoculaire druk (intraocular pressure, IOP) waarden aan boven het 
niveau dat door clinici als veilig wordt beschouwd. Een chronisch verhoogde 
oogdruk kent als zodanig geen symptomen en kan alleen met tonometrie worden 
vastgesteld. De kans om glaucoom te ontwikkelen stijgt met de oogdruk. Andere 
bekende risicofactoren zijn etniciteit en leeftijd en er is een erfelijke component. 
 
Glaucoom wordt gekarakteriseerd door beschadiging van de optische zenuw. Dit 
veroorzaakt vermindering van de visuele functie. Gewoonlijk manifesteert de ziekte 
zich initieel door uitval in het perifere gezichtsveld. Het kan lang duren voordat 
patiënten hier daadwerkelijk hinder van ondervinden en dit als symptoom herken-
nen. In een latere fase kan glaucoom zich ontwikkelen tot tunnelzien en ten slotte 
tot blindheid, een proces dat onomkeerbaar is. Hoewel glaucoom ongeneeslijk is, 
kan de progressie van glaucoom worden geremd door therapie. Aangezien de 
snelheid van progressie afhankelijk is van de oogdruk, is glaucoomtherapie gericht 
op het verlagen van de IOP. In klinische onderzoekstrials is aangetoond dat IOP 
verlagende therapie het risico vermindert dat OH patiënten glaucoom ontwikkelen 
(zie de Ocular Hypertension Treatment Study) en dat het bij POAG patiënten 
inderdaad een beschermd effect heeft t.a.v. de progressie (zie de Early Manifest 
Glaucoma Trial en de Advanced Glaucoma Intervention Study). Er is echter een 
grote spreiding in het vermogen van OH en POAG patiënten om een verhoogde 
oogdruk te verdragen. Niet alle OH patiënten ontwikkelen glaucoom zonder thera-
pie, terwijl ondanks een IOP verlagende therapie sommige POAG patiënten wel 
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progressie van glaucoom vertonen. Dit maakt duidelijk dat een verhoogde oogdruk 
niet de enige factor is in de pathogenese en de progressie van glaucoom. Momenteel 
is echter oogdruk de enige bekende factor in de ontwikkeling van glaucoom waarop 
medische behandeling gericht kan worden. Therapieën betreffen oogdrukverlagende 
medicatie, laserbehandeling en chirurgie. Het hoofddoel van elk van deze therapie-
en is het behoud van de visuele functie en het voorkomen van verdere progressie 
naar de eindfasen van de ziekte. Voor een succesvolle aanpak van glaucoom is het 
belangrijk dat patiënten in een vroegtijdig stadium worden ontdekt. Er bestaan 
verschillende technieken die gebruikt kunnen worden bij de diagnostiek van glau-
coom: oogdrukmeting (tonometrie), visualisatie van de papil van de optische zenuw 
(ophthalmoscopie) en bepaling van het gezichtsveld (perimetrie). Gewoonlijk is een 
combinatie van deze technieken benodigd om de diagnose glaucoom te bevestigen. 
 
Voor een effectief management van glaucoom is een gedetailleerd inzicht in de 
effecten van de behandelmethoden cruciaal. Aangezien glaucoom een chronische 
ziekte is, dient men de langetermijneffecten in ogenschouw te nemen. Dit is lastig, 
omdat de meeste klinische trials slechts een beperkte follow-up kennen. Recent zijn 
echter de resultaten van enkele grote klinische trials beschikbaar gekomen waarin 
patiënten over een lange periode werden gevolgd. Een ander hoofdthema voor het 
management van deze chronische ziekte wordt gevormd door de behandelkosten. In 
de laatste decennia zijn deze substantieel gestegen ten gevolge van de introductie 
van nieuwe types oogdrukverlagende middelen. Deze middelen zijn duur, maar ze 
hebben de bestaande behandelmogelijkheden verruimd. Tegenwoordig heeft men de 
beschikking over een breed spectrum aan middelen. Er zijn nu verschillende opties 
voor het starten van een therapie wanneer er contraindicaties zijn voor klassieke 
oogdrukverlagende middelen. Ook wanneer er geen of te weinig verlaging van de 
IOP wordt bereikt met een voorgeschreven middel, of wanneer bijwerkingen optre-
den, is alternatieve medicatie voorhanden. Ten slotte zijn er verschillende medicij-
nen die aan een reeds voorgeschreven medicatie kunnen worden toegevoegd wan-
neer een verdere verlaging van de IOP wenselijk is. Het is derhalve een gecompli-
ceerde kwestie om tot ideale behandelstrategieën te komen voor OH en POAG 
patiënten, waarbij veel factoren in beschouwing dienen te worden genomen. 
 
Een van de kernvragen is of patiënten met oculaire hypertensie wel of niet behan-
deld dienen te worden. Per slot van rekening hebben deze patiënten nog geen 
glaucoom, althans niet in een mate die met de huidige diagnostische technieken is 
vast te stellen. Behandeling gaat niet alleen gepaard met kosten, maar ook met 
ongemak en mogelijkerwijs met bijwerkingen van de medicatie. De resultaten van 
dit proefschrift wijzen op een gunstig effect van behandeling van OH patiënten: 
medicamenteuze oogdrukverlaging leidt tot een kleinere kans op het ontwikkelen 
van glaucoom. Om het effect van behandeling te bepalen is een langdurige follow-
up nodig en dienen de incidenties van glaucoom bij patiënten met en zonder behan-
deling te worden vergeleken. Hoewel in het verleden OH patiënten vaak wel behan-
deld werden, had dit tot voor kort geen bewezen nut. In hoofdstuk 2 is alle beschik-
bare wetenschappelijk bewijs m.b.t. het effect van de behandeling van oculaire 
hypertensie samengebracht in een systematische literatuurstudie. De uitkomsten van 
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negen gerandomiseerde klinische trials, waarbij OH patiënten met en zonder IOP 
verlagende behandeling werden gevolgd, zijn gecombineerd in een meta-analyse. 
Deze analyse toont aan dat een IOP verlagende therapie bij OH patiënten de kans 
op het ontwikkelen van glaucoom vermindert. Het gepoolde relatieve risico be-
draagt 0,61 (met een 95% betrouwbaarheidsinterval van 0,45-0,83). Tevens is 
gevonden dat het relatieve risico afneemt met 14% met iedere mm Hg oogdrukver-
laging. Momenteel is er onvoldoende kennis beschikbaar om OH patiënten te 
identificeren die een verhoogd risico lopen op het ontwikkelen van glaucoom als 
behandeling uitblijft. Therapie voor OH patiënten wordt algemeen geadviseerd bij 
hoge IOP waarden of in aanwezigheid van andere risicofactoren. Veel OH patiënten 
in de trials hebben echter IOP waarden onder het niveau waarboven behandeling 
geadviseerd wordt, en bij lang niet iedereen is er sprake van andere risicofactoren. 
Verder onderzoek in deze richting is daarom gewenst. 
 
De gedachte achter de verschillende strategieën voor het detecteren en behandelen 
van patiënten met oculaire hypertensie en beginnend glaucoom, is dat het uiteinde-
lijk blindheid voorkomt. Hoofdstuk 3 beschrijft een case-referent studie waarin het 
effect van vroege opsporing van OH en POAG patiënten op het optreden van 
blindheid ten gevolge van glaucoom wordt onderzocht. Voor een groep ‘cases’ en 
voor een groep ‘referents’ wordt nagegaan in welke mate men in het verleden te 
maken kreeg bij de oogarts met screening tests voor de vroege opsporing van OH 
en POAG, zonder dat er directe aanleiding toe was vanwege symptomen. De groep 
‘cases’ wordt gevormd door blinde glaucoompatiënten. De groep ‘referents’ repre-
senteert de algehele populatie t.a.v. de frequentie waarmee dergelijke tests worden 
uitgevoerd. De grondredenering in deze studie is als volgt. Als patiënten zonder 
symptomen tests ondergaan voor het opsporen van OH en POAG, dan kan de ziekte 
in een vroeg stadium worden opgespoord en behandeld. Als de behandeling van OH 
en beginnende POAG effectief is ter voorkoming van blindheid, dan is te verwach-
ten dat dergelijke patiënten gewoonlijk geen blindheid zullen ontwikkelen. Omge-
keerd kan worden gepostuleerd dat de reden dat blinde glaucoompatiënten blind 
zijn geworden, is dat zij niet bijtijds opgespoord (en behandeld) werden. De uit-
komsten van deze studie bevestigen deze veronderstelling. Blinde glaucoompatiën-
ten ondergingen minder vaak de screening tests waarmee OH en POAG kunnen 
worden opgespoord dan de ‘referents’. Het berekende relatieve risico is 0,57 (met 
een 90% betrouwbaarheidinterval van 0,31-1,05). Deze studie laat zien dat vroege 
opsporing van patiënten met OH en POAG in de oogartsenpraktijk effectief is ter 
voorkoming van blindheid. 
 
Momenteel bestaat er geen aanbeveling voor een screeningsprogramma voor glau-
coom onder de gehele bevolking. Het beste alternatief voor een vroege opsporing 
van zulke patiënten is case-finding onder de patiënten die een oogarts bezoeken. Er 
zijn verschillende manieren om dit onderwerp te benaderen. Een interessante vraag 
m.b.t. case-finding in de oogartsenpraktijk is of de IOP routinematig gemeten zou 
dienen te worden bij alle nieuw binnenkomende patiënten, of alleen bij een selecte 
groep van patiënten met risicofactoren voor glaucoom. Ophthalmoscopie, waarmee 
de papil van de optische zenuw kan worden bekeken, maakt normaliter deel uit van 
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een ophthalmologisch onderzoek. Tonometrie dient echter alleen ter bepaling van 
een verhoogde oogdruk. Deze test kan eenvoudig worden uitgevoerd zonder veel 
ongemak voor de patiënt. Een gevolg van het routinematig testen met tonometrie is 
dat meer patiënten, hoofdzakelijk OH patiënten, zullen worden opgespoord en 
behandeld. Behalve een klinisch effect heeft dit ook een effect op de kosten. In 
hoofdstuk 4 worden de langetermijnkosten en -effecten van drie verschillende case-
finding strategieën bestudeerd en geëvalueerd met behulp van een beslismodel. 
Hierbij wordt tonometrie routinematig uitgevoerd: (1) bij alle nieuw binnenkomen-
de patiënten, (2) alleen bij hoogrisico patiënten, (3) bij niemand. Deze strategieën 
worden vergeleken met methoden uit de kosteneffectiviteitanalyse. De conclusie 
luidt dat het het meest kosteneffectief is ter voorkoming van blindheid t.g.v. glau-
coom, om tonometrie uit te voeren bij alle nieuw binnenkomende patiënten. De 
extra kosten per gered jaar met zicht bedragen € 1.707 in vergelijking tot de strate-
gie waarbij tonometrie bij niemand wordt uitgevoerd. Het is aannemelijk dat de 
kosten die in geval van blindheid door een patiënt per jaar worden gemaakt als 
gevolg van deze handicap, dit bedrag ruim overstijgen. 
 
De belangrijkste kosten bij de behandeling van glaucoom zijn de kosten van de 
medicatie. De introductie van de nieuwe types glaucoommiddelen heeft bijgedragen 
aan veranderingen in het prescriptiepatroon, en is hand in hand gegaan met een 
aanzienlijke toename van de behandelkosten. Lange tijd waren niet-selectieve 
bètablokkers zoals timolol de eerste medicijnkeuze bij behandeling. Tegenwoordig 
worden hypotensieve lipiden zoals latanoprost vaak gebruikt als eerstelijnstherapie. 
De oogdrukverlagende werking van latanoprost is slechts een weinig sterker dan die 
van timolol. Anderzijds ligt de kostprijs van latanoprost een stuk hoger. De kosten 
en de klinische effecten van medicijnen dienen beide in beschouwing te worden 
genomen bij de keuze van een type medicatie. Dit geldt in het bijzonder voor 
medicijnen waarmee de behandeling geïnitieerd wordt, aangezien veel patiënten het 
voor lange tijd zullen gaan gebruiken. Als voldoende IOP verlaging wordt bereikt 
zonder het optreden van bijwerkingen, dan zal een patiënt op de betreffende medi-
catie worden gehouden. Een vervanging of toevoeging van een medicijn vindt 
alleen plaats wanneer daartoe een noodzaak bestaat. Voor patiënten met oculaire 
hypertensie is het niet nodig om de IOP evenveel te verlagen als bij glaucoompati-
enten. Men kan zich daarom afvragen, in het licht van de hogere prijs voor hypoten-
sieve lipiden, of het gerechtvaardigd is om de behandeling van OH patiënten met 
dergelijke middelen te initiëren. 
 
In hoofdstuk 5 wordt een onderzoek beschreven, waarin de klinische langetermijn-
effecten van het initiëren van OH therapie met timolol en met latanoprost worden 
bestudeerd en vergeleken. In hoofdstuk 6 wordt een kosteneffectiviteitanalyse van 
deze twee strategieën gegeven. Hiertoe wordt een simulatiemodel gebruikt. In dit 
model wordt niet alleen met de initiatie van de therapie rekening gehouden, maar 
ook met de eventueel daaropvolgende aanpassingen. Het uiteindelijke verschil 
tussen de twee strategieën voor wat betreft de bereikte IOP verlaging is klein. 
Aangezien de kans op het ontwikkelen van glaucoom afhangt van de IOP, is ook het 
verschil in optredende blindheid t.g.v. glaucoom klein. Gemiddeld is dit ongeveer 1 
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maand per persoon voor beide strategieën, met een gemiddeld verschil tussen de 
strategieën van 2 dagen blindheid per patiënt. Daar staat tegenover dat het verschil 
in behandelkosten tussen de twee strategieën groot is. Dit maakt duidelijk waarom 
het initiëren van de behandeling van OH patiënten met latanoprost extreem hoge 
incrementele kosten met zich meebrengt in vergelijking tot het initiëren van de 
behandeling met timolol. Bij de huidige kostprijs van latanoprost bedragen deze 
extra kosten per gered jaar met zicht € 537.000. 
 
Hoofdstuk 7 sluit dit proefschrift af met een algemene discussie en een vooruitblik 
op toekomstig onderzoek. Aanbevelingen voor zulk onderzoek zijn het ontwikkelen 
van preciezere richtlijnen die aangeven wanneer de behandeling van OH patiënten 
gestart dient te worden, evenals het identificeren van deelgroepen van patiënten 
waarop behandelstrategieën kunnen worden toegesneden.  
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eens op niveau gehouden. Jullie beider spontaniteit en gevoel voor humor maakte 
de samenwerking prettig en nooit saai.  
 
Mijn dank gaat natuurlijk ook uit naar mijn beide promotoren, prof. Martin Prins en 
prof. Fred Hendrikse. Martin, de regelmatige bijeenkomsten in de eindfase van het 
schrijven waren onmisbaar voor de afronding van dit werk. Bedankt voor je tijd en 
alle plezierige schrijfsessies. Prof. Hendrikse, de jaren die ik heb doorgebracht bij 
de afdeling oogheelkunde zijn zeer aangenaam geweest. De manier waarop u 
iedereen weet te motiveren en daarmee zorgt voor het hoge niveau van de afdeling 
is heel bijzonder. Behalve de professionele en educatieve momenten was er ook 
vaak gelegenheid voor intellectuele ontspanning, zoals de onvergetelijke party’s aan 
het begin van elk jaar. Bedankt voor alles. 
 
Aan de fijne werkomgeving bij de afdeling oogheelkunde hebben velen bijgedra-
gen: stafartsen, arts-assistenten, medewerkers van het secretariaat en van de poli. In 
het bijzonder wil ik noemen mijn kamergenoten Henny Beckers en Noël Bauer. Dat 
jullie destijds hebben aangeboden mij te huisvesten op jullie (niet al te ruime) 
kamer waardeer ik nog steeds zeer. Ik zal jullie gezellige gezelschap blijven missen. 
En natuurlijk Martin Buissink. Toen je in ons eerste gesprek na een paar minuten 
vroeg of ik de ‘Subterranean Homesick Blues’ kende wist ik dat het goed zat. Astrid 
Hacking, bedankt voor alle support door de jaren heen. Aukje, Yanny, Suzanne en 
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Rob, mede-onderzoekers op de afdeling en tevens mede-lunchgangers, het was leuk 
om jullie te leren kennen en met jullie op te trekken. Benjamin, bedankt voor je 
inzet. John, Tos, het is altijd leuk jullie weer eens op de gangen tegen te komen. 
Iedereen op het secretariaat, met name Ellen, bedankt voor al jullie hulp. Het is 
altijd gezellig om bij jullie binnen te lopen. En dank aan alle arts-assistenten en 
kersverse oogartsen, ik wens jullie het beste! 
 
Het lijkt nu lang geleden, maar toen ik in september 2001 begon aan dit onderzoek 
was dat bij de capaciteitsgroep Epidemiologie. Ik heb er nieuwe kennis en kennis-
sen opgedaan, veel leuke mensen leren kennen, en vriendschappen aan overgehou-
den. Mijn dank aan prof. Piet van den Brandt voor de mogelijkheid om bij Epide-
miologie te starten. In deze fase van het onderzoek was Renée Rijnders betrokken 
bij het project, bedankt voor je werk en voor je gezelligheid. Maurice Zeegers en 
Pieter Leffers, jullie wil ik tevens bedanken voor jullie wetenschappelijke bijdra-
gen. Jos Slangen bedank ik voor alle ondersteuning op computergebied en zijn 
vermogen om meteen daar te verschijnen waar hulp nodig is. Mijn voorganger op 
het gebied van glaucoomonderzoek was Rikkert van der Valk. Rikkert, bedankt, 
ook voor al die keren dat je me weer eens met de auto kwam ophalen voor een 
refereeravond. En dank aan Raymond, Patty, Nicky en Ludo, en alle anderen die op 
een of andere manier hebben meegeholpen tijdens dit onderzoek. 
 
Een groot gedeelte van dit proefschrift gaat over modelleren en kosteneffectiviteit. 
De expertise op dit gebied ligt bij de afdeling Kemta van het AZM waar ik vooral 
heb samengewerkt met prof. Hans Severens. Hans, bedankt voor je professionele 
maar ook persoonlijke inzet. Op jacht naar de kosten, een niet te verwaarlozen maar 
moeilijk in te vullen aspect van een kosteneffectiviteitmodel, kreeg ik hulp van 
Manuela Joore en Gemma Vos. Hiervoor wil ik jullie allebei bedanken.  
 
De leden van de leescommissie, prof. Limburg, prof. Luyten, prof. Knottnerus, prof. 
Van Schayck, dr. Busch wil ik allemaal graag bedanken voor het lezen en beoorde-
len van mijn proefschrift. 
 
Carolien Bastiaenen, Peter Brouwers, mijn paranimfen. Ieder van jullie een vriend 
waarmee altijd veel te lachen valt. Bedankt, dat jullie deze taak hebben willen 
vervullen.  
 
Een paar woorden nog aan een aantal vrienden die ik niet ongenoemd wil laten. 
Harry, dank voor alle muzikale gedachtewisselingen. Ik denk dat het de Gibson L00 
was die het vaakst uit zijn koffer is geweest tijdens het schrijven van dit boek. 
Huub, een vriendschap kan ontstaan uit een onverwachte situatie, ik heb er veel aan 
gehad in de laatste twee jaar.  
 
En ten slotte een plekje voor mijn familie, verspreid door Nederland, Slowakije en 
Tsjechië. Dat maakt het niet gemakkelijk qua taalkeuze! Dan maar eerst in het 
Nederlands. Jo en Netty, ik weet dat ik niet veel hoef te zeggen maar toch bedankt 
voor alle steun en interesse in mijn werk. Ralf, je bent al die tijd mijn grootste steun 
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geweest! Je hebt me vaak genoeg moed ingepraat. Bedankt voor alle hulp en nog 
veel meer wat mij lief is en wat ik eigenlijk alleen voor ons wil houden. Ook be-
dankt voor de constante bevoorrading met de bluesnummers die mij op de been 
houden. Lieve Thomas, je hebt me vaak genoeg geholpen met je optimisme en je 
goede zin. Bovendien kwamen jouw handige computertrucjes soms goed van pas. 
Je hebt buitengewoon veel begrip gehad als ik weer eens geen tijd voor je had 
omdat ik bezig was met het proefschrift. Ik ben trots op je. Dear Kaťa, my dear 
sister, now that I am finishing this work, I would like more than anything that our 
parents would enjoy it too. But that was not meant to be. This work is dedicated to 
them as well. I know that you have done very much in these last two years and I 
was not always able to help you. Thank you for everything, ďakujem! 
 
 
Andrea Peeters  
Maastricht, november 2007 
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